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Summary 
Aneuploidy is a rare condition in untransformed cells and one of the hallmarks of cancer. It often 
coexists with chromosomal instability and correlates with intra-tumor heterogeneity and poor clinical 
outcome. Several studies performed in various organisms engineered to harbor chromosome 
abnormalities have revealed that aneuploidy confers common phenotypes such as intracellular 
pathway deregulation and increased energy and metabolic requests, all eventually impairing cellular 
fitness. Even if the majority of aneuploid cells are less proliferatively active than normal diploid cells, 
favorable karyotypic variants and selection pressure can confer a growth advantage to 
chromosomally unstable cells, due to their improved adaptability, possibly promoting tumorigenesis.  
As a rare event in normal tissues, aneuploidy constitutes an attractive potential therapeutic target 
for cancer treatment. Indeed, some studies have started to investigate this opportunity, mainly in 
cell line models, leading to the identification of some compounds that specifically target aneuploidy. 
Acute myeloid leukemia (AML) patients with aneuploid karyotypes respond poorly to conventional 
chemotherapy. Thus, the identification of aneuploidy-specific antiproliferative compounds that could 
be used for the treatment of this subset of AML patients constitutes an intriguing strategy. 
Here we show that 8-azagunanine is a potential aneuploidy-selective antiproliferative compound in 
AML. 8-Azaguanine causes endoplasmic reticulum stress, possibly exacerbating proteotoxic stress as 
one of the predominant features of aneuploid cells, and specifically enhances the death of cells with 
abnormal karyotypes. 
Moreover, we demonstrate in AML cells that p53 deficiency enables the propagation of extensive 
karyotypic heterogeneity and chromosome abnormalities including structural aneuploidy (gains or 
losses of sub-chromosomal regions) and structural rearrangements (alterations of chromosome 
structure), which are conversely prevented in p53-proficient cells. Numerical aneuploidy, on the 
other hand, does not inevitably trigger p53 activation. These results suggest that p53 provides 
maintenance of genomic stability especially with regard to structural chromosome abnormalities. 
Zusammenfassung 
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Zusammenfassung  
Aneuploidie tritt selten in untransformierten Zellen auf und stellt ein Kennzeichen von Krebs dar. 
Sie tritt häufig in Verbindung mit chromosomaler Instabilität auf und korreliert mit Intra-Tumor-
Heterogenität und infauster Prognose. Mehrere Studien an verschiedenen Modellorganismen mit 
Chromosomenanomalien haben gezeigt, dass Aneuploidie eine Deregulierung der intrazellulären 
Signalwege und eine erhöhte Energie- und Stoffwechselanforderung verursacht, was schließlich die 
zelluläre Fitness beeinträchtigt. Obwohl der Großteil aneuploider Zellen eine eingeschränkte 
Proliferation aufweist, können günstige karyotypische Varianten und Selektionsdruck einen 
Wachstumsvorteil für die chromosomal instabilen Zellen bedeuten, welcher die Tumorgenese 
unterstützen kann. 
Da Aneuploidie nur selten in normalem Gewebe nachzuweisen ist, repräsentiert sie ein attraktives 
therapeutisches Ziel für die Entwicklung von Krebstherapien. Aus diesem Grund wurden aneuploide 
Zelllinien bereits in Studien für die Entwicklung aneuploidie-selektiver Wirkstoffe verwendet. 
Patienten mit akuter myeloischer Leukämie (AML), die einen aneuploiden Karyotyp aufweisen, 
sprechen schlecht auf eine konventionelle Chemotherapie an. Daher stellt die Identifizierung 
aneuploidie-selektiver antiproliferativer Wirkstoffe eine attraktive Strategie zur Behandlung dieser 
AML Patienten dar. 
In dieser Arbeit konnten wir zeigen, dass 8-Azagunanin eine aneuploidie-selektive Wirkung in der 
akuten myeloischen Leukämie besitzt. 8-Azaguanin ruft eine Stressreaktion im endoplasmatischen 
Retikulum hervor, die möglicherweise proteotoxischen Stress, ein Hauptmerkmal von aneuploiden 
Zellen, verstärkt und somit in Zellen mit abnormalem Karyotyp häufiger zu Zelltod führt. 
Darüber hinaus konnten wir in AML Zellen zeigen, dass das Fehlen von p53 die Weitergabe 
umfangreicher karyotypischer Heterogenität und Chromosomenanomalien, einschließlich 
struktureller Aneuploidie (Gewinn oder Verlust subchromosomaler Regionen) und Umlagerungen 
(Veränderungen der Chromosomenstruktur) ermöglicht, die im Vergleich dazu in p53-kompetenten 
Zellen verhindert werden. Hingegen löst eine numerische Aneuploidie die Aktivierung von p53 nicht 
zwangsläufig aus. Diese Ergebnisse legen nahe, dass p53 die Aufrechterhaltung der genomischen 
Stabilität, insbesondere im Hinblick auf strukturelle Chromosomenanomalien, gewährleistet.  
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1 Introduction 
1.1 Aneuploidy 
The term aneuploidy was coined in 1922 by Gunnar Täckholm
1
 and refers to a condition in which the 
number of chromosomes within a cell differs from the whole multiple of the haploid number for a 
certain species. Indeed, the term aneuploidy derives from the Greek an meaning not, eu meaning 
good and ploos meaning fold: “not the right fold”. Aneuploidy can be caused by gains and losses of 
entire chromosomes (numerical or whole chromosome aneuploidy)  and by gains and losses of parts 
of chromosomes  (structural or segmental aneuploidy). Aneuploidy differs from polyploidy, defined 
by the acquisition of entire sets of chromosomes (Fig. 1).  
 
Figure 1 | Euploid, polyploid and aneuploid karyotypes 
 
Euploidy refers to the normal genomic state of a species. Depending on the species, euploidy can 
describe a haploid, diploid or polyploid karyotype. On the other hand, aneuploidy is an aberrant 
genomic state that describes a range of karyotype abnormalities including chromosome losses and 
gains as well as duplications, deletions or unbalanced translocations of sub-chromosomal regions.  
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1.1.1 Aneuploidy in normal tissues 
Aneuploidy is a rare event in untransformed tissues. When aneuploidy is caused by errors which 
occur during germ cell formation, usually during meiosis, it is termed constitutional aneuploidy. 
Somatic aneuploidy (mosaicism), by contrast, results from a post-zygotic event as a consequence of 
mitotic errors. While constitutional aneuploidy affects all the cells of a multicellular organism, in 
mosaicism only some cells harbor an aberrant karyotype.  
The consequences of aneuploidy are typically detrimental in many living beings from yeast to plants 
and mammals. Thus, the preservation of a correct chromosome set is indispensable for the 
development and survival of an organism. In humans, constitutive autosomal chromosome gains are 
normally incompatible with survival until adulthood, with the exception of Down syndrome (47, XY, 
+21) where the presence of an extra chromosome 21 results in a complex pathologic phenotype. 
Individuals with Edward (47, XY, +18) and Patau (47, XY, +13) syndromes die shortly after birth. All 
autosomal losses cause embryonic lethality. Sex chromosome aneuploidies, such as Turner (45, X) 
and Klinefelter (47, XXY) syndromes, also show developmental defects even if they have less adverse 
consequences than autosomal aneuploidy probably due to less genetic contribution of X and Y 
chromosomes.  
Mosaic aneuploidy can be benign; some normal cells such as neuronal progenitors, neurons and 
hepatocytes have been described to show a certain level of aneuploidy
2,3,4,5,6
. Nevertheless, more 
recent findings contradict these results arguing that the aneuploidy level in brain and liver is not 
different from that in skin and involves fewer than 5% of cells
7
. Mosaicism can also cause abnormal 
phenotypes. A rare disorder termed mosaic variegated aneuploidy (MVA) syndrome manifests with 
growth retardation, microcephaly and cancer at young age
8
. Among others, mutations in the BUB1B 
gene, required for correct chromosome segregation, have a causal role in MVA development
9
. 
Mosaicism can affect both somatic and germ line cells. When gametes are involved, some of them 
are normal while others carry chromosome aberrations which eventually are inherited by the 
offspring. 
Mosaicism frequency increases with age and  this phenomenon seems also to be associated with 
neurodegenerative diseases
10
 and with cancer development
3,11,12,13
. 
Given the adverse effects of aneuploidy, it is not unexpected that perturbed chromosome 
segregation fidelity is a rare event in untransformed cells. Indeed, the rate of chromosomal 
segregation errors in these cells is only approximately 0.025% per chromosome, with an estimate of 
global chromosomal missegregation of one chromosome every 100 cell divisions
14
.  
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1.1.2 Aneuploidy in cancer 
Whereas aneuploidy occurs rarely in normal tissues, it is a common characteristic of both solid and 
hematological malignancies. About 85% of all human cancers harbor an aneuploid karyotype
15
. Many 
cancer cells, besides harboring aneuploidy, are characterized by high rates of chromosome 
missegregation, namely chromosomal instability (CIN), which leads to extensive genome 
heterogeneity within tumor tissues
16
. Aneuploidy is furthermore associated with poor prognosis
17
 
indicating that chromosome missegragation contributes to cancer progression and increasing genetic 
diversity among cancer cells which can acquire novel phenotypes such as drug resistance. 
Whether aneuploidy and CIN contribute to tumor initiation and progression or constitute a mere 
epiphenomenon of cell transformation is still an open issue.  
The possible role of aneuploidy in cancer progression was already foreseen in 1890 by David von 
Hansemann who identified multipolar divisions in epithelial tumor cells
18
. Moreover, the 
observations made at the beginning of the twentieth century by the German biologist Theodor 
Boveri, who was studying aneuploid cells generated in sea urchin embryos undergoing multipolar 
divisions, led to the hypothesis that tumors could develop from normal cells that have become 
aneuploid after aberrant mitosis
19
.  
The discovery of oncogenes and tumor-suppressor genes made scientists conceive the idea that 
specific mutations in these genes might be responsible for cancer development and that aneuploidy 
could be just a consequence of neoplastic transformation
20
. At the same time, however, mounting 
evidence that aneuploidy could trigger tumorigenesis gained new support. For example, trisomy of 
chromosome 8, which is harbored by approximately 15% of individuals with AML besides other blood 
cells malignancies, seems to promote blood tumor development
21
. Indeed, trisomy 8 causes the 
presence of an extra copy of MYC, an oncogene that could drive hematopoietic stem cell malignant 
transformation.  
Moreover, recent work again supports a role of reduced mitotic fidelity and aneuploidy in early steps 
of tumorigenesis
22,23
. Transient Mad2 overexpression in transgenic mice leads to CIN, which may take 
place before cell transformation and tumor formation in a wide spectrum of tissues. Additionally, 
MAD2 has been described to be upregulated in a subset of human cancer types
22
. Furthermore, 
aneuploidy caused by increased rates of numerical chromosome missegregation in Cenp-E
+/-
 mice 
promotes tumorigenesis, giving rise to splenic lymphomas and lung adenomas, without evidence of 
additional defects. However, the same animals were less likely to develop spontaneous liver tumors 
and tumors provoked by exposure to a carcinogen, thus leading to the conclusion that CIN can act 
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both as tumor promoter and tumor suppressor
23
. This double-sided nature of CIN might be explained 
by the observation that low missegregation rates can be tolerated and become tumor-promoting, 
whereas cells with high rates of missegregation cannot survive, resulting in tumor suppression
24
.  
1.1.3 Pathways leading to aneuploidy 
The maintenance of a euploid karyotype after each cell division is the result of a perfect interaction 
among the components of the chromosome segregation machinery. However, errors which give rise 
to daughter cells that have gained or lost genetic material can occur. Mechanisms described as major 
contributors to aneuploidy include defects of the spindle assembly checkpoint (SAC), erroneous 
microtubules-kinetochore interactions, chromatid cohesion defects and supernumerary 
centrosomes. 
1.1.3.1 Impaired Spindle Assembly Checkpoint  
The SAC prohibits anaphase onset in absence of stable microtubule-kinetochore attachments and 
kinetochore tension. SAC proteins are recruited to the outer surface of unattached kinetochores 
inhibiting the activation of the E3 ubiquitin ligase CDC20-APC, or anaphase promoting complex 
(APC/C), and the subsequent degradation of securin and cyclin B1. Once the checkpoint requests are 
satisfied, APC/C mediates the ubiquitination of securin and cyclin B1, whose degradation leads to the 
activation of separase. Separase activity induces cohesin cleavage and the ensuing sister-chromatid 
separation, cyclin-dependent kinase 1 (CDK1) inactivation and mitotic exit. Mutations or reduced 
concentrations of these proteins may impair checkpoint functionality. Cells might enter anaphase 
with unattached or misaligned chromosomes causing missegregation of sister-chromatids into the 
same daughter cell. The majority of studies that describe a correlation between weakened SAC 
activity and high incidence of aneuploidy and tumorigenesis have been performed in mouse models. 
Mice heterozygous for SAC-related genes show high levels of aneuploidy in comparison to wild-type 
controls
25,26,27
. However, in human cancer, mutations in SAC genes are rare
28
. Consistently, the 
majority of primary cancer cells have been described to have an intact SAC
29,30
. 
1.1.3.2 Erroneous microtubule-kinetochore interactions 
During mitosis progression the establishment of correct interactions between microtubules and 
kinetochores is fundamental. Microtubules bind and release kinetochores several times until sister 
kinetochores have bound to opposite spindle poles. Correct microtubule-kinetochore configuration is 
called amphitelic attachment (Fig. 2A) and only when all kinetochores are connected to microtubules 
in an amphitelic orientation cells can proceed into anaphase. However, erroneous orientation 
frequently occurs in early mitosis and must be corrected in order to have accurate chromosome 
    Introduction 
 
8 
 
segregation into daughter cells. The SAC is able to detect some types of erroneous microtubule-
kinetochore attachments such as monotelic and syntelic ones, whereas merotelic attachments are 
not sensed by the checkpoint.   
Monotelic attachments (Fig. 2B) result from the capture of microtubules by just one of the sister-
kinetochores and lead to the movement of both sister-chromatids to one pole. In cells with an active 
SAC, it is unlikely that aneuploid daughter cells arise by this type of attachment error as the presence 
of one unattached kinetochore is already sensed by the mitotic checkpoint
31
.  
Syntelic attachments (Fig. 2C) occur when microtubules from one spindle pole bind to both sister-
kinetochores of a chromosome, leading to activation of the SAC and prevention of anaphase entry as 
well
32
.  
Merotelic attachments (Fig. 2D), conversely, occur when microtubules generated from both spindle 
poles bind to the same kinetochore. In this case, sufficient tension necessary to inactivate the SAC is 
established and cells can proceed into anaphase without any mitotic delay
33
. For this reason, 
chromosomes bound to both spindle poles are either segregated to the pole from which the thicker 
microtubules bundle nucleates or maintained at the metaphase plate after anaphase onset, 
constituting lagging chromosomes. Merotelic orientations thus have the potential to drive cell 
transformation and carcinogenesis even in cells with an active SAC
34,35
. 
    Introduction 
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Figure 2 | Microtubule-kinetochore attachments 
 
Amphitely describes the correct state of microtubule-kinetochore attachment. Monotely, syntely and 
merotely represent erroneous microtubule-kinetochore connections. 
1.1.3.3 Chromatid cohesion defects 
More recent analyses suggest that chromatid cohesion defects might be involved in aneuploidy and 
cancer progression. These errors lead to a premature separation of sister-chromatids and to the 
subsequent failure of an equal segregation of chromosomes into daughter cells. Mutations in many 
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genes encoding for cohesion complex subunits have been frequently found in various human tumor 
types
36,37,38
. Nevertheless, many of the patients described to harbor mutations in those genes have 
normal karyotypes, suggesting that other mechanisms of action of these proteins might be involved 
in the transformation process 
39,40,38
. 
1.1.3.4 Supernumerary centrosomes 
Mechanistically, the presence of supernumerary centrosomes is believed to be the main cause of 
chromosome missegregation
41
. Indeed, centrosome aberrations are recurrent in the majority of 
cancers, both solid and hematological
42,43,44,45
, and correlate with karyotype abnormalities and poor 
prognosis. Supernumerary centrosomes can arise from centriole overduplication, de novo centriole 
synthesis, mitotic slippage, aborted cell division and cell fusion
46
. Chromosome missegregation can 
result from a transient multipolar spindle in which merotelic attachments occur before 
supernumerary centrosomes cluster into a bipolar spindle
47
 (Fig. 3). More recently, an additional 
mechanism has been described: mitoses which immediately follow centriole overduplication are 
bipolar, with a centriole rosette at one or both spindle poles (Fig. 3). Mitotic rosettes at the two poles 
of a mitotic spindle frequently harbor an unbalanced centriole number which correlates with the 
number of nucleated microtubules. Consequently, the spindle pole with the rosette containing more 
centrioles captures more chromosomes, increasing the probability to establish merotelic attachment 
defects and causing lagging chromosomes
48
.  
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Figure 3 | Centrosome clustering and centriole rosettes 
 
Both types of centrosome aberrations cause erroneous merotelic microtubule-kinetochore 
attachments. 
1.1.4 Consequences of aneuploidy 
Several studies performed on aneuploid yeast, mammalian cell lines, flies and plants have revealed 
that all of these organisms display shared phenotypes which can be attributed to aneuploidy, such as 
pathway deregulation (DNA and RNA metabolism; endoplasmic reticulum, Golgi apparatus and 
lysosome function; membrane and mitochondrial metabolism), hampered proliferation and 
increased energy and metabolic requests. 
1.1.4.1 Inhibition of cell proliferation 
Typically, aneuploidy comes with a fitness cost. Aneuploid cells generally grow slow and are prone to 
replication stress, ensuing DNA damage and gene mutations. Cultured skin fibroblasts from patients 
with Down syndrome have a significantly longer doubling time relative to cells of healthy donors with 
the same age
49
. Aneuploid yeast strains show G1-phase delay and even those which do not exhibit a 
proliferative impairment have a lower growth capacity than wild-type strains
50
. Furthermore, G1 
delay has been described in human engineerized trisomic cells as well
51
. An altered proliferative 
capacity has also been detected in trisomic mouse embryonic fibroblasts (MEFs) and correlates with 
the size of the additional chromosome
52
. Together, these observations indicate that impaired 
proliferation is a common finding in aneuploid cells.  
1.1.4.2 Transcriptional responses and effects on the proteome 
Chromosome number alterations markedly influence the physiology of organisms. The mechanisms 
responsible for the detrimental effects of aneuploidy are still not completely unraveled, but it has 
been shown that aneuploidy causes changes at both transcriptional 
50,52,51,53,54
 and protein 
levels
51,55,56
.  
In both yeast and humans, it has been demonstrated that the expression of the majority of genes 
which are present at additional chromosome copies is proportionately increased
50,52,51,54
. Although in 
most of the cases the amount of proteins scales with gene copy number, some proteins which are 
encoded by genes present on extra chromosomes are buffered to diploid levels. Among these 
proteins maintained at stoichiometric levels, several reports list protein complex subunits
50,51,55,57
 and 
protein kinases
51
. 
Conversely, a peculiar feature named “aneuploidy-associated protein signature (APS)” has been 
described in disomic versus wild-type yeast. It implies the upregulation of proteins associated with 
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cellular response to oxidative stress without an increase of the corresponding transcripts, possibly 
due to protein stabilization
55
. 
Interestingly, studies in budding yeast indicate that the altered phenotypes associated with 
chromosome aberrations are due to the relative amount of supernumerary genes. Indeed, 
phenotype abnormalities derived from the acquisition of a single chromosome are more emphasized 
in haploid than diploid yeast
50
.  
In addition to the increased mRNA abundance derived from the presence of supernumerary 
chromosomes, the expression of other genes is often altered in aneuploid cells as well. This occurs as 
a consequence of the overexpression of regulatory proteins which influence expression of genes 
present on other chromosomes and/or as a consequence of the activation of specific responses to 
aneuploidy
50,53,58
. Derived phenotypes are thus the result of concurrent changes in the transcript 
amount of many genes, which would have only little impact on cellular function individually. The 
response to the aneuploid state occurs independently of the identity of the extra chromosome and 
seems to be conserved, involving similar pathways in different organisms, from plants to mice and 
humans
58
. It mainly implies the upregulation of pathways related to cellular stress and membrane 
metabolism as well as the downregulation of pathways connected to nucleic acid metabolism and 
cell proliferation
51,53
. 
1.1.4.3 Proteotoxic stress 
Proteotoxic stress is one of the most prominent features of aneuploid cells. It results from the 
accumulation of unfolded or misfolded proteins due to altered and overwhelmed regulatory 
mechanisms which preserve protein homeostasis. In normal cells chaperone-mediated protein 
folding, as well as proteasome and autophagy activation, ensure that only an appropriate amount of 
proteins and their active forms are maintained. Many subunits of protein complexes are unstable 
until they bind to their partners and for this reason they interact with chaperones in order to 
maintain their solubility. If no partner is found, they are degraded by proteases. In aneuploid cells 
protein stoichiometries are impaired and this affects the quality control machinery. Enhanced 
protein production, which occurs in karyotypically aberrant cells, induces saturation of the protein 
folding pathways, which in turn leads to protein misfolding and degradation. It has been proposed 
that subsequent chronic proteotoxic stress may inhibit the activity of additional factors fundamental 
for the cellular response to this pathological state, resulting in a vicious cycle. 
The molecular chaperone heat shock protein 90 (HSP90), whose client proteins are mostly kinases 
and signal transduction proteins, has been shown to have diminished activity and folding capacity in 
aneuploid yeast strains
59
. In line with these findings, aneuploid versions of human immortalized 
retinal pigment epithelial (RPE-1) cells and tumorigenic human colon cancer (HCT116) cells have 
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consistently lower amounts of HSP90 transcripts and protein levels than their diploid cognates, 
probably due to defective activation of heat shock factor 1 (HSF1)
60
. Both aneuploid yeast strains and 
human cell lines are also more sensitive to chaperone inhibitors geldanamycin and 17-AAG, in 
comparison to euploid cells
50,60
. By contrast, trisomic MEFs harbor increased heat shock protein 72 
(HSP72) levels. Despite this difference they are still sensitive to the HSP90 inhibitor 17-AAG, 
suggesting that defective HSP90 protein folding activity represents a conserved consequence of 
aneuploidy 
61
. 
Aneuploidy also compromises protein degradation pathways. Aneuploid yeast strains exhibit 
hampered proliferation after treatment with the proteasome inhibitor MG132 at concentrations 
which do not affect euploid cells as well as after treatment with drugs which interfere with protein 
synthesis
50
. Moreover, inactivating mutation of the proteasome-associated deubiquitinating enzyme 
UBP6 gene reverses the negative effect of aneuploidy on protein composition and cellular fitness
57,55
. 
Conversely, proteasome-mediated degradation of proteins and autophagy seem to be increased in 
mammalian cells with an abnormal karyotype. Indeed, trisomic MEFs do not show the same 
sensitivity to proteasome inhibitors as yeast and exhibit an increased lipidated form of the autophagy 
marker light chain 3 (LC3)
61
. Similarly, LC3 foci are also increased in aneuploid human cell lines in 
which p62/sequestosome-1 (SQSTM1)-mediated autophagy takes place
51
. Further studies proposed 
the idea that, due the overloaded chaperone capacity and compromised proteasome activity, 
misfolded proteins form aggregates which become included into autophagosomes. Subsequent 
lysosomal saturation triggers lysosome stress response. Indeed, TFEB, a regulator of genes involved 
in autophagy, is overexpressed in aneuploid cells in order to generate additional autophagosome and 
lysosome activity
62
. Thus, increased lysosomal burden contributes to the reduction of cellular fitness 
and to augmented sensitivity of trisomic MEFs to the lysosome inhibitor chloroquine
61
. 
1.1.4.4 Genomic instability 
It is becoming evident that the presence of an altered karyotype has a detrimental effect on genome 
stability. It has been shown that budding yeast strains with abnormal karyotypes display increased 
rates of chromosome missegregation, mitotic recombination and DNA damage. Aneuploid strains are 
also more sensitive to genotoxic agents
63
. Similarly, human cell lines with extra copies of a single 
chromosome exhibit DNA damage as shown by increased 53BP1 foci in G1 cells. Furthermore, these 
cells are more sensitive to agents inducing replication stress such as aphidicolin
64
.  
Genomic rearrangements occur frequently due to lagging chromosome breakage during cytokinesis 
leading to chromosomal deletions and translocations
65
. Chromosomes which lag behind during 
anaphase, even if segregated properly, are frequently not incorporated with the other chromosomes 
into the newly forming nucleus, but form separate micronuclei instead. Micronuclei can persist for 
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several cell division cycles. DNA replication within micronuclei is often defective and mitotic entry 
can occur before micronuclear DNA replication has been concluded
66
. As a consequence, 
chromosomes entrapped in micronuclei frequently become fragmented in a process called 
chromothripsis
67
, which designates a one-time catastrophic event during which chromosomes or 
chromosome arms are shattered into fragments. When these fragments are subsequently stitched 
together by DNA repair mechanisms, intrachromosomal rearrangements including deletions, 
duplications, inversions and translocations occur. These rearranged chromosomes can join the main 
nucleus in subsequent mitoses generating both numerical and structural chromosomal instability. 
Chromothripsis has been described in many types of malignancies and is found in about 2-3% of 
cancers
67
. 
1.1.5 Cellular tolerance to aneuploidy 
Although the detrimental effects of aneuploidy and CIN are well described, karyotype imbalances 
may confer proliferative advantages and promote tumorigenesis. Under certain circumstances 
aneuploidy can have a tumor suppressor role, but once aneuploid cells overcome certain limitations, 
aneuploidy itself becomes beneficial for cancer development. 
Chromosome missegregation may be accompanied by DNA damage, structural aberrations and 
subsequent genomic instability, which can be the driver of tumor evolution. Loss of tumor 
suppressor genes and gain of oncogenes lead to impairment of signaling pathways that normally 
restrict aneuploid cell proliferation, thus allowing cells to tolerate the adverse effects of aneuploidy 
and tumor evolution. For example, TP53 (also known as p53) activation is known to be triggered by 
errors in chromosome segregation
65,68,69
, even if the aspects of chromosome missegregation that 
cause p53 activation are still not clarified and multiple mechanisms might be responsible
70
. TP53, at 
the same time, is one of the most frequently mutated genes in human cancers, arguing that 
mutations of genes that suppress the antiproliferative effects of aneuploidy and CIN are important 
factors in carcinogenesis. 
Aneuploidy generates phenotypic diversity that might induce a selective advantage for tumor 
evolution in a changing environment. Even if the majority of aneuploid cells is less proliferatively 
active than normal diploid cells, favorable karyotypic variants and selection pressure can confer a 
growth advantage to chromosomally unstable cells due to their improved adaptability
71,72
.   
It seems that in certain cases aneuploid cells, in order to survive, become polyploid. The gain or loss 
of a single chromosome seems to have a greater impact on haploid compared to diploid and 
tetraploid cells and thus the acquisition of an additional chromosome set may attenuate the 
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consequences of aneuploidy, balancing gene dosage alterations
73
.  
Additionally, compensatory events such as the degradation of certain proteins (e.g. the members of 
protein complexes
50,51
)
 
might be important for the re-establishment of stoichiometric balance and 
aneuploidy tolerance. 
1.1.6 Aneuploidy as a therapeutic target 
Since aneuploidy is a hallmark of cancer associated with poor prognosis and a rare event in normal 
tissues, it constitutes an attractive potential therapeutic target. Some studies have started to 
investigate this opportunity. With the idea to interfere with pathways compromised in aneuploid 
cells, Tang et al. identified compounds (AICAR, 17-AAG and chloroquine) that show specificity against 
triploid MEFs
61
. They seem to exaggerate the basal stress associated with chromosome copy number 
changes. Interestingly, AICAR and 17-AAG impair the growth of colon cancer cell lines with CIN. The 
combination of the two drugs is even more effective with regard to inhibition of cell viability
61
. 17-
AAG shows selective efficacy also against trisomic and tetrasomic HCT116 cells and trisomic human 
immortalized RPE-1 cells
60
. More recently, an additional drug screening reported that several agents 
which stimulate the activation of the AMP-activated protein kinase (AMPK), such as resveratrol, 
piceatannol, salicylates, AICAR, and A-769662, selectively eliminate tetraploid cells in diverse cancer 
cell lines as well as in vivo
74
. Tetraploid cells are transitionally found in pre-malignant lesions and 
early stages of multiple tumor cell types before they develop aneuploid karyotypes by chromosomal 
loss in mitosis 
75,76
. Additionally, 8-azaguanine and DPBQ have been shown to be more effective 
against high-ploidy RPE-1 and breast epithelial MCF10A cells compared to their diploid 
counterparts
77
. 
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1.2 Acute myeloid leukemia 
Acute myeloid leukemia (AML) is a clonal malignancy of hematopoietic progenitor cells characterized 
by arrest of differentiation, uncontrolled proliferation and the consequential presence of atypical 
immature myeloid cells, called blasts, in bone marrow, peripheral blood and other tissues. Early signs 
and symptoms, which are mainly attributable to progressive bone marrow insufficiency, are 
paleness, weakness, shortness of breath and tachycardia (due to anemia), easy bruising or 
haemorrhages (due to thrombocytopenia) and susceptibility to infections (due to granulocytopenia). 
Symptoms and signs caused by the infiltration of liver, spleen, lymph nodes, skin and central nervous 
system can also occur. 
1.2.1 Epidemiology 
AML is the most common acute leukemia in adults. It has a higher prevalence in elderly people, with 
a median age at diagnosis of 68 years
78
. The incidence of new cases seems to be rising over the years, 
probably due to the increasing age of the population and to previous exposition to toxic agents or 
chemotherapy. AML can occur after progression of other hematological diseases or as a consequence 
of prior cytotoxic therapy, but it arises de novo in most of the cases
79,80
. An older age at diagnosis is 
associated with worse prognosis. The disease is currently cured in 35-40% of patients younger than 
60 and only in 5-15% of older patients
81
. With intensive induction therapy complete remission is 
reached in 60-80% of young patients and 40-60% of elderly patients
82
; however, in most individuals 
the disease relapses within 3 years after diagnosis
81
. 
1.2.2 AML classifications 
In the 1970s AML was initially classified according to the French-American-British (FAB) classification 
system considering morphologic features of blasts
83
. AML was divided in 8 classes, M0-M7, on the 
basis of the hematopoietic lineage and differentiation status of the neoplasm. Starting from 2002 the 
World Health Organization (WHO) classification has almost completely replaced the FAB 
classification. It assigns a strong importance to cytogenetic and molecular genetic features besides 
the morphologic and immunophenotypic evaluation
84,85
. 
1.2.3 Diagnosis 
Procedures currently used to diagnose AML include complete blood count and differential leukocyte 
count, morphologic studies of bone marrow specimens and blood smear, immunophenotyping of cell 
surface and cytoplasmic markers, cytogenetics and molecular genetic studies.  
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Morphology and immunophenotypic features are used to assess the blast lineage and to evaluate the 
level of maturation of the neoplastic cells. According to WHO guidelines, AML is diagnosed by the 
presence of >20% of blasts among total cells in either bone marrow (BM) or peripheral blood (PB) 
after the analysis of at least 200 leukocytes in PB and 500 nucleated cells in BM
86
. Cytogenetic studies 
together with the screening for selected mutations constitute mandatory diagnostic procedures 
because certain abnormalities are strongly correlated with long-term prognosis and allow for specific 
treatment.  
1.2.4 Prognostic factors 
Thanks to the progress made in the next-generation-sequencing field, the molecular heterogeneity of 
AML has been highlighted and genetic abnormalities have gained increasing interest not only as 
diagnostic markers, but also as prognostic factors. Indeed, according to the European LeukemiaNet 
(ELN) recommendations, AML is classified into three prognostic risk groups which take into account 
both karyotype abnormalities and genetic mutations: favourable, intermediate and adverse (Tab. 
1)
82
. 
Risk Group Abnormalities 
Favourable t(8;21)(q22;q22.1); RUNX1-RUNX1T1 
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11  
Mutated NPM1 without FLT3-ITD or with FLT3-ITD
low 
Biallelic mutated CEBPA 
Intermediate Mutated NPM1 and FLT3-ITDhigh 
Wild-type NPM1 without FLT3-ITD or with FLT3-ITD
low 
(without adverse-risk 
genetic lesions) 
t(9;11)(p21.3;q23.3); MLLT3-KMT2A 
Cytogenetic abnormalities not classified as favorable or adverse 
Adverse t(6;9)(p23;q34.1); DEK-NUP214  
t(v;11q23.3); KMT2A rearranged  
t(9;22)(q34.1;q11.2); BCR-ABL1 
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)  
-5 or del(5q); -7; -17/abn(17p)  
Complex karyotype, monosomal karyotype 
Wild-type NPM1 and FLT3-ITD
high
 
Mutated RUNX1 
Mutated ASXL1 
Mutated TP53 
 
Table 1 | AML risk groups and respective abnormalities according to ELN recommendations 
 
t: translocation; inv: inversion; del: deletion; abn: abnormal. 
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Recurrent mutations in leukemia-associated genes such as FLT3, NPM1, C-KIT, N-RAS, CEBPA, WT1, 
ASXL1, DNMT3A, MLL, TET2, IDH1 and IDH2 have been identified. Nevertheless, more than 25% of 
AML patients carry no mutations in those genes
87
. NPM1, FLT3 and CEBPA mutation screening has 
been introduced into routine clinical practice
88
. Indeed, CEBPA biallelic mutations and mutated 
NPM1, in presence of wild-type FLT3-ITD, are considered favorable prognostic risk factors 
independently of other coexisting abnormalities
89,90
, whereas patients with mutations in both NPM1 
and FL3-ITD genes are classified into the intermediate risk group. By contrast, FLT3-ITD mutations in 
the absence of NPM1 mutations confer an adverse risk
82
. Thus, the prognostic impact of one factor 
can be strongly dependent on the presence or absence of other abnormalities.  
1.2.5 Complex karyotype 
An abnormal karyotype is found in approximately 60% of patients with AML
91
. Among all 
chromosome aberrations t(8;21)(q22;q22.1), inv(16)(p13.1q22) or t(16;16)(p13.1;q22) and t(15;17) 
are considered markers of good prognosis, independently of the presence of additional 
abnormalities. t(6;9)(p23;q34.1), t(v;11q23.3), t(9;22)(q34.1;q11.2), inv(3)(q21.3q26.2) or 
t(3;3)(q21.3;q26.2), monosomy 5 or del(5q), as well as monosomy 7 and 17 or abn(17p) are instead 
included in the adverse risk group together with complex and monosomal karyotypes
92
. According to 
the ELN criteria a complex karyotype is defined by the presence of three or more chromosome 
aberrations, in the absence of recurrent translocations or inversions including t(8;21), inv(16) or 
t(16;16), t(15;17), t(9;11), t(6;9), t(v;11q23.3), t(9;22), inv(3) or t(3;3)
82
. Aberrations such as derivative 
chromosomes, marker chromosomes, ring chromosomes and double minutes should also be taken 
into account
93,94,95
. In AML cells chromosomal losses are more frequent than chromosomal gains
96
. 
Approximately 10-14% of all AML patients and 23% of elderly patients harbor a complex karyotype 
and their prognosis is dismal despite intensive treatment
97,98
. 
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1.3 Aim of the project 
The aim of this study is to identify compounds which show selective activity against aneuploid AML 
cells and to further investigate the mechanisms leading to this specific effect. 
The general treatment approach for AML has been maintained similar for the last 40 years
99
. Indeed, 
conventional therapy for most patients consists in the combination of the nucleoside analog 
cytarabine and the anthracycline daunorubicin. Since patients with aneuploid karyotypes respond 
poorly to conventional chemotherapy there is a high clinical need for the development of new 
compounds and new therapeutic approaches. The advances made in the identification of recurrent 
cytogenetic aberrations and mutations in AML suggest development of specific therapies for 
different AML subgroups
100
. The introduction of drugs with selective efficacy against aneuploid 
karyotypes appears as a reasonable and competitive approach in patients affected by complex 
karyotype AML. Indeed the effectiveness of the use of compounds specifically targeting aneuploidy 
has already been proven in other models. 
For this purpose, first, compounds including drugs already described as selectively active against 
aneuploid cells and some other anti-cancer drugs were tested on AML primary samples. 
Subsequently an isogenic AML cell line model was generated to evaluate the specific efficacy of the 
identified aneuploidy-selective antiproliferative compounds and the mechanisms involved in their 
action. 
Since p53 might limit the propagation of aneuploidy and p53 loss is frequently found in complex 
karyotype AML, we also introduced a TP53 knock-out into the AML EEB cell line. We aimed at 
expanding the number of clones that constitute the model by the development of new different 
karyotypic aberrations and testing the compounds of interest in a p53-deficient setting as well. 
Furthermore, we investigated whether p53 deficiency is sufficient to cause aneuploidy and CIN in 
AML cells and whether p53-deficient and p53-proficient AML cells tolerate segregation errors to a 
different extent.  
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2 Material 
2.1 Material for cell biology methods 
2.1.1 Patient material 
34 bone marrow aspirates or peripheral blood samples from patients with acute myeloid leukemia, 
characterized by the presence of at least 80% of blasts, were provided by the Department of Internal 
Medicine V, University Hospital Heidelberg and by the Department of Medicine Clinic and Polyclinic I, 
University of Dresden. Cells were cultured in Mononuclear Cell Medium (MCM) supplemented with 
0.5 µg/ml gentamicin and 2.5 µg/ml amphotericin B. 
2.1.2 Cell lines 
Name Origin Characteristics Culture conditions 
EEB 
Homo sapiens, 
AML 
EEB cell line was provided by the 
RIKEN BRC through the National 
Bio-Resource Project of the 
MEXT, Japan 
StemSpan SFEM, 
15% FBS 
1C1 - 46, XY 
Derived from single cell seeding 
of EEB cell line 
1C6 - 46, X, -Y 
Derived from single cell seeding 
of EEB cell line 
5C3 - 90, XX, -Y, -Y 
Derived from single cell seeding 
of EEB cell line 
MC3 - 47, XY, +12 
Derived from single cell seeding 
of EEB cell line after treatment 
with CENP-E and MPS1 inhibitors 
MC7 - 47, X, -Y, +7, +21 
Derived from single cell seeding 
of EEB cell line after treatment 
with CENP-E and MPS1 inhibitors 
MC27 - 47, XY, +22 
Derived from single cell seeding 
of EEB cell line after treatment 
with CENP-E  and MPS1 inhibitors 
10-1 
Derived from 1C1 – 46, XY cell 
line after p53 knock-out 
9-5 
Derived from 1C1 – 46, XY cell 
line after p53 knock-out 
8-1 
Derived from 1C1 – 46, XY cell 
line after p53 knock-out 
Table 2 | Cell lines 
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2.1.3 Media and supplements for cell culture 
Name Company, Catalogue number 
Mononuclear Cell Medium (MCM) PromoCell, Cat. No. C-28030 
StemSpan SFEM STEMCELL Technologies, Cat. No 09650 
Fetal Bovine Serum (FBS) Clontech, Cat. No. 631106 
Gentamicin  Sigma-Aldrich, Cat. No. G1272-10ML 
Amphotericin B Biochrom, Cat. No. A 2612 
Table 3 | Media and supplements for cell culture 
2.1.4 Buffers and solutions for mononuclear cells extraction 
Name Ingredients, Company, Catalogue number 
Biocoll separating solution  Biochrom AG, Merk Millipore, Cat. No. L6115 
1x Dulbecco’s Phosphate Buffered Saline  
(D-PBS)  
Life Technologies, Cat. No. 14200067 
Erythrocyte lysis buffer NH4Cl 1.5M, KHCO3 0.10M, EDTA 1mM, pH 7.3 
Table 4 | Buffers and solutions for mononuclear cells extraction 
2.1.5 Compounds  
Name Company, Catalogue number 
AICAR Cayman Chemical, Cat. No. Cay10010241-50 
Cytarabine Cayman Chemical, Cat. No. Cay16069-500 
Daunorubicin Cayman Chemical, Cat. No. Cay14159-5 
Metformin Cayman Chemical, Cat. No. Cay13118-1 
Vincristine Cayman Chemical, Cat. No. Cay11764-5 
Acetylsalycilic acid Sigma-Aldrich, Cat. No. A5376-100G 
Chloroquine Sigma-Aldrich, Cat. No. C6628-25G 
Cisplatin Sigma-Aldrich, Cat. No. P4394-25MG 
Resveratrol Sigma-Aldrich, R5010-100MG 
8-Azaguanine Santa Cruz, Cat. No. sc-207194 
Paclitaxel AdipoGen, Cat. No. AG-CN2-0045-M005 
17-AAG Selleckchem, Cat. No. S1141 
Crenolanib Selleckchem, Cat. No. S2730 
Centrinone MedChemexpress Co., Ltd., Cat. No. HY-18682 
Table 5 | Compounds tested   
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2.1.6 Reagents for fixation and cell staining 
Name Ingredients, Company, Catalogue number 
Acetone Sigma-Aldrich, Cat. No. 179973-2.5L 
Methanol Sigma-Aldrich, Cat. No. 32213-2.5L 
Parafolmaldehyde Applichem, Cat. No. A3813,1000 
Acetic acid glacial Fisher Scientific, Cat. No. 10171460 
Triton X-100 Sigma-Aldrich, Cat. No. 114K0182 
Blocking solution 10% goat serum in 1x PBS 
Goat serum Life Technologies, Cat. No. 16210064 
Fluoromount-G™ eBioscience, Cat. No. 00-4958-02 
Vectashield antifade mounting medium  Vector Laboratories, Cat. No. H-1000 
Table 6 | Reagents for fixation and cell staining 
2.1.7 Primary antibodies for immunofluorescence staining or Western blotting 
Name  Clone Species Dilution Company, Catalogue number 
ɣH2AX JBW301 Mouse (m) 1:1000 Merck Milllipore, Cat. No. 05-636 
Actin C4 Mouse (m) 1:5000 
Santa Cruz Biotechnology,  
Cat. No. sc-47778 HRP 
Caspase-2 11B4 Rat (m) 5 µg/ml Merck Milllipore, Cat. No. MAB3507 
Caspase-3 3G2 Mouse (m) 1:1000 Cell Signalling, Cat. No. 9668 
Cleaved Caspase-3 
Asp175 
5A1E Rabbit (m) 1:1000 Cell Signalling, Cat. No. 9664 
Caspase-8 p18 2B12.1 Mouse (m) 2 µg/ml 
Merck Milllipore,  
Cat. No. MAB10754 
Caspase-9 C9 Mouse (m) 1:1000 Cell Signalling, Cat. No. 9508 
CHOP L63F7 Mouse (m) 1:1000 Cell Signalling, Cat. No. 2895 
GAPDH 411 Mouse (m) 1:2000 
Santa Cruz Biotechnology,  
Cat. No. sc-47724 
HGPRT EPR5299 Rabbit (m) 1:5000 Abcam. Cat. No. ab109021 
MCM7 142.1 Mouse (m) 1:2000 
Santa Cruz Biotechnology,  
Cat. No. sc-9966 
PARP 46D11 Rabbit (m) 1:1000 Cell Signalling, Cat. No. 9532 
p44/45 MAPK 
(Erk1/2)  
 Rabbit (p) 1:1000 Cell Signalling, Cat. No. 9102 
Phospho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 
D13.14.4E Rabbit (m) 1:1000 Cell Signalling, Cat. No. 4370 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
98F2 Rabbit (m) 1:1000 Cell Signalling, Cat. No. 4671 
   Material 
 
23 
 
p53 Bp53.11 Mouse (m) 1:5000 Progen, Cat. No.61039 
p21 DCS60 Mouse (m) 1:2000 Cell Signalling, Cat. No. 2946 
Table 7 | Primary antibodies 
(m) monoclonal; (p) polyclonal 
2.1.8 Secondary antibodies for immunofluorescence staining or Western blotting 
Name Fluorochrome Species Dilution Company, Catalogue number 
Mouse IgG 
Alexa Fluor 
488 
Goat (p) 1:1000 Life Technologies, Cat. No. A11029 
Mouse IgG 
Alexa Fluor 
568 
Goat (p) 1:1000 Life Technologies, Cat. No. A11031 
Rabbit IgG 
Alexa Fluor 
488 
Goat (p) 1:1000 Life Technologies, Cat. No. A11034 
Rabbit IgG 
Alexa Fluor 
568 
Goat (p) 1:1000 Life Technologies, Cat. No. A11036 
IgG anti-mouse IgG 
(H+L)-HRPO 
 Goat (p) 1:10000 
Jackson immuno research,  
Cat. No. 115-035-003 
IgG anti-rabbit IgG 
(H+L)-HRPO 
 Goat (p) 1:10000 
Jackson immuno research, 
Cat. No. 111-035-003 
IgG anti-rat IgG  
(H+L)-HRPO 
 Goat (p) 1:10000 
Jackson immuno research, 
Cat. No. 112-035-003 
Table 8 | Secondary antibodies 
(p) polyclonal 
2.1.9 Cell stains 
Name  Dilution Company, Catalogue number 
Hoechst 33342, 
trihydrochloride, trihydrate 
Stock: 10 mg/ml, 1:1000 Life Technologies, Cat. No. H1399 
Propidium Iodide Stock: 1 mg/ml, 1:100 Life Technologies, Cat. No. P3566 
Table 9 | Cell stains 
2.1.10 Small molecules and inhibitors 
Name Treatment conditions Company, Catalogue number 
Thymidine 2 mM, for 24 h Sigma-Aldrich, Cat. No. T1895-5G 
NMS-P715  480 nM, for 24 h Merck Millipore, Cat. No. 475949-
5MG 
GSK923295  50 nM, for 24 h Selleckchem, Cat. No. S7090 
U0126 1 µM, 2.5 µM, for 48h Promega, Cat. No. V1121 
Table 10 | Small molecules and inhibitors 
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2.1.11 Reagents for cell viability testing and caspase activity analysis 
Name Company, Catalogue number 
TC10 Trypan Blue Dye 0,4%  Bio-Rad Laboratories GmbH,  
Cat. No. 145-0013 
CellTiter-Glo® 2.0 Assay  Promega, Cat. No. G9242 
WST-1 Roche, Cat. No. 11644807001 
Caspase-Glo® 3/7 Assay  Promega, Cat. No. G8091 
Table 11 | Reagents for cell viability testing and caspase activity analysis 
2.1.12 Reagents and solutions for metaphase preparation 
Name Ingredients, Company, Catalogue number 
Colcemid  Biochrom, Cat. No. L 6221 
Hypotonic solution 0.075 M KCl 
Table 12 | Reagents and solutions for metaphase preparation 
2.1.13 Kits 
Name Company, Catalogue number 
Annexin V Apoptosis Detection Kit 1 Becton Dickinson, Cat. No. 556547 
Neon™ Transfection System 10 µL Kit 
(Buffer R, Electrolytic Buffer E) 
Invitrogen, Cat. No. MPK1096 
Table 13 | Kits for cell biology methods 
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2.2 Material for protein biochemistry methods 
2.2.1 Reagents and material for cell lysis and Western blotting 
Name Ingredients, Company, Catalogue number 
Protein lysis buffer, RIPA 50 mM Tris/HCl pH 7.4, 1% NP-40, 0.25% Sodium 
deoxycholate, 1 mM NaCl, 1 mM EDTA, 1 tablet 
per 50ml Complete Protease inhibitor, 5 tablets 
per 50 ml Phospho-Stop  
cOmplete™ tablets EASYpack Roche, Cat. No. 05892970001 
PhosStop™ EASYpack Roche, Cat. No. 04906837001 
Quick Start™ Bradford 1x Dye Reagent Bio-Rad Laboratories, Cat. No. 500-0205 
6x SDS sample loading buffer 7 ml 1M Tris-Cl/0.4% SDS pH 6.8, 3 ml Glycerol,  
1 g SDS, 0.93 g DTT, 0.01% bromophenol blue 
Precision Plus Protein™ Dual Color Standards  Bio-Rad Laboratories, Cat. No. 161-0394 
Acrylamide/Bis-Acrylamide 30% Acrylamide, 0.15% Bis-Acrylamide 
Solution B 3 M Tris-Base, 0.4% SDS, pH 8.8 
Solution C 0.75 M Tris-Base, 0.4% SDS, pH 6.8 
Rotiphorese® Gel 30 (37,5:1) Roth, Cat. No. 3029.1 
Separating gel Acrylamide/Bis-Acrylamide, Solution B, ddH2O 
(volumes were adjusted according to gel 
percentage) 
Stacking gel Rotiphorese® Gel 30 (37,5:1), Solution C, ddH2O 
(volumes were adjusted according to gel 
percentage) 
Electrode buffer 0.6% Tris-Base, 2.87% Glycine, 0.1% SDS 
APS 10% APS in ddH2O 
TEMED Serva Electrophoresis, Cat. No. 35925.01 
Trans-Blot® Turbo™ RTA Transfer Kit, PVDF  Bio-Rad Laboratories, Cat. No. 1704272 
Skim Milk Powder Gerbu, Cat. No. 1602.025 
BSA Applichem, Cat. No. A1391,0250 
1x TBS-T 10 mM Tris, 150mM NaCl, 0.1% Tween 20 
Clarity™ Western Blotting ECL Substrate  Bio-Rad Laboratories, Cat. No. 170-5061 
Table 14 | Reagents and materials for cell lysis and Western blotting 
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2.3 Material for molecular biology methods 
2.3.1 Media for bacteria transformation 
Name Ingredients 
SOB Medium 2% Trypton, 0.5% Yeast extract, 0.05% NaCl, 2.5 
mM KCl, 10 mM MgCl2, pH 7.0  
SOC Medium SOB medium, 20 mM Glucose 
LB medium 1% Trypton, 0.5% Yeast extract, 1% NaCl 
pH 7.2 
LB agar LB medium, 1.5% Agar 
Table 15 | Media for bacteria transformation 
2.3.2 Buffers and loading dyes for DNA and RNA electrophoresis 
Name Ingredients, Company, Catalogue number 
6x DNA loading dye 100 mM Tris/HCl pH 7.5, 100 mM Tris/HCl pH 
7.5, 200 mM EDTA, 0.01% Bromophenol, 0.01% 
Blue Xylencyanol, 30% Glycerol  
10x TAE buffer 400 mM Tris/HCl pH 8.0, 10 mM EDTA, 200 mM 
Acetic acid 
LowRanger DNA Ladder  Norgen Biotek, Cat. No. 11500 
 
RNA Sample Loading buffer  Sigma-Aldrich, Cat. No. R4268-1VL 
10x MOPS buffer 200 mM MOPS, 50 mM Sodium acetate, 10 mM 
EDTA, pH 6.6 
Table 16 | Buffers and loading dyes for DNA and RNA electrophoresis 
2.3.3 Primers for PCR and sequencing 
Name Sequence Manufacturer 
p53-long isoforms-Fwd 5´- CTGGTCCTCTGACTGCTCTTTTC - 3´ 
Eurofins MWG Operon 
p53-long isoforms-Rev 5´- TAGAGACGAGGTTTCATCATGTTACC - 3´ 
p53-all isoforms-Fwd 5´- CTAGCTCGCTAGTGGGTTGCA - 3´ 
p53-all isoforms-Rev 5´- AGTGCTGGGATTACAGGCATGAG - 3´ 
p53-all isoforms-Fwd 5´- TGTAGACGCCAACTCTCTCTAGC - 3´ 
p53-all isoforms-Rev 5´- GGATTACAGGCATGAGCCACTG - 3´ 
hU6-Fwd 5'-GAGGGCCTATTTCCCATGATT-3' 
Table 17 | Primers for PCR and sequencing 
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2.3.4 Plasmid used for transfection 
Name Company, Catalogue number 
pSpCas9(BB)-2A-Puro (PX459) V2.0 Addgene, Cat. No. 62988 
Table 18 | Plasmid used for transfection 
2.3.5 Enzymes and reagents 
Name Company, Catalogue number 
BbsI HF New England Biolabs, Cat. No. R3539S 
CutSmart® Buffer New England Biolabs, Cat. No. B7204S 
Shrimp Alkaline Phosphatase  Thermo Fisher Scientific, Cat. No. 783901000UN 
T4 Polynucleotide Kinase New England Biolabs, Cat. No. B0201S 
T4 Polynucleotide Kinase Reaction Buffer  New England Biolabs, Cat. No. B0201S 
NxGen T4 DNA Ligase  Lucigen, Cat. No. 30241-1-LU 
10x T4 ligase buffer Lucigen, Cat. No. 30241-1-LU 
RNase A Analytik Jena, Cat. No. A3832,0500 
CloneAmp™ HiFi PCR Premix Clontech, Cat. No. 639298 
Phusion® High-Fidelity DNA Polymerase  New England Biolabs, Cat. No. M0530S 
Table 19 | Enzymes and reagents 
2.3.6 sgRNA 
Target Exon targeted Sequence Manufacturer 
p53-all isoforms 1 3 5´- GCAGTCACAGCACATGACGGAGG -3´ 
Eurofins MWG 
Operon 
p53-all isoforms 2 3 5´- CGCTATCTGAGCAGCGCTCATGG - 3´ 
p53-long isoforms 1 4 5´- GGCAGCTACGGTTTCCGTCTGGG - 3´ 
p53-long isoforms 2 4 5´- CCCCGGACGATATTGAACAATGG - 3´ 
Table 20 | sgRNA 
2.3.7 Antibiotic for transfected cell selection 
Name Company, Catalogue number 
Puromycin Addgene, Cat. No. 62988 
Table 21 | Antibiotic for transfected cell selection 
2.3.8 Kits 
Name Company, Catalogue number 
QIAmp DNA Mini Kit Qiagen, Cat. No. 51304 
RNeasy Mini Kit  Qiagen, Cat. No. 217004 
RNase-Free DNase Set  Qiagen, Cat. No. 79254 
QIAprep Spin Miniprep Kit  Qiagen, Cat. No. 27106 
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Plasmid Maxi Kit Qiagen, Cat. No. 12163 
High Pure PCR Product Purification Kit  Roche, Cat. No. 11732676001 
Guide-it™ sgRNA In Vitro Transcription Kit Takara, Cat. No. 632635 
Guide-it™ Complete sgRNA Screening System Takara, Cat. No. 632636 
Qubit RNA BR Assay Kits Invitrogen, Cat. No. Q10210 
Table 22 | Kits for molecular biology methods 
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2.4 Laboratory equipment 
2.4.1 General lab devices 
Name Company 
Accuri C6 flow cytometer  Becton Dickinson 
Agarose detection system Intas 
Agarose gel casting system  BioRad Laboratories 
Centrifuge 5408R Eppendorf 
Centrifuge 5417R  Eppendorf 
Centrifuge Megafuge 1.0R  Heraeus 
Centrifuge Sorvall RC6Plus Thermo Fisher Scientific 
ChemiDoc™ Touch Imaging System  Bio-Rad Laboratories 
Electrophoresis chamber BioRad Laboratories 
Fine scale, LA120S Sartorius 
Heat stirrer, MR Hei-Standard Heidolph 
Incubator for bacteria Memmert 
Incubator for cell culture, C200 Labotec BeLoTec 
Flex Cycler
2 
Analytik Jena 
pH-Meter SevenMulti  Mettler Toledo 
Biophotometer Eppendorf 
Polyacrilamyde gel casting system BioRad Laboratories 
Consort EV power supply unit Sigma-Aldrich 
Qubit fluorometer Invitrogen 
Shaker for bacteria, SM-30 Control Edmund Bühler 
Shaker for Western blot membranes, ST5 CAT 
Shandon Cytospin III  Thermo electron corporation 
Spark microplate reader  TECAN 
Spectrophotometer NanoDrop 2000 PeqLab Biotechnologie Erlangen 
Sterile hood, Hera safe KS Thermo electron corporation 
TC20™ automated cell counter  Cell Bio-Rad Laboratories 
Thermomixer comfort Eppendorf 
Trans-Blot® Turbo™ System  Bio-Rad Laboratories  
UV Table  Konra Benda  
Vortex Genie2 Scientific industries 
Waterbath Thermomix ME B.Braun 
Table 23 | General lab devices 
 
 
 
   Material 
 
30 
 
2.4.2 Devices used for cell transfection 
Name Company 
Neon™ Transfection System Invitrogen 
Neon™ Transfection System Pipette Invitrogen 
Neon™ Transfection System Pipette Station Invitrogen 
Table 24 | Devices for cell transfection 
2.4.3 Microscopes  
Name  Company 
Cell observer.Z1  
equipped with AxioCam MRm  
Carl Zeiss 
Fluorescence microscope Axioskop 
equipped with AxioCam MRm 
Carl Zeiss 
DMIL Leica 
Table 25 | Microscopes 
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2.5 Software 
Name  Company 
BD Accuri™ C6 Becton Dickinson 
ZEN lite 2011 Carl Zeiss 
ImageJ Wayne Rasband 
Image Lab™ Bio-Rad Laboratories 
Microsoft Office 2010 Microsoft Corporation 
GraphPad Prism version 7  GraphPad Software 
Ingenuity® Pathway Analysis IPA® QIAGEN 
Table 26 | Software 
2.6 Reagents 
Molecular biology grade or purest available reagents were obtained from the following companies: 
Applichem, Arcos Organics, Carl Roth, Fisher Scientific, Fluka Chemicals, Gerbu, Merck Millipore, 
Serva Electrophoresis, Sigma-Aldrich.  
2.7 Consumables 
Consumables from the following companies were employed: GE Healthcare, Starlab, Sarstedt, 
Eppendorf and Whatman. 
2.8 Solution preparation 
All solutions were prepared with double distilled water or Milli-Q® water. Solutions were sterilized by 
autoclaving them for 20 min at 121°C or by filtration through 0.22 μm filters. Solutions were stored 
at room temperature unless otherwise stated.  
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3 Methods 
3.1 Cell biology methods 
3.1.1 Mononuclear cell isolation 
Bone marrow mononuclear cells (BMNCs) and peripheral blood mononuclear cells (PBMCs) were 
isolated by density gradient centrifugation. 20 ml of bone marrow aspirates or peripheral blood were 
layered on 15 ml of Biocoll separating solution. The solution was spun down at 425 rcf in a swinging-
bucket rotor for 15 minutes without brake. After centrifugation the mononuclear cells were isolated 
from the interphase between Biocoll and serum. Cells were washed in 1x D-PBS and red blood cells 
were lysed for 10 minutes in the dark in 1x erythrocyte lysis buffer/Milli-Q® water when needed. In 
order to inactivate the lysis buffer cells where washed in 1x D-PBS. 
3.1.2 Cell culture 
Cells were maintained at 37°C in a humidified 5% CO2 environment. Primary cells were cultured in 
Mononuclear Cell Medium (MCM) supplemented with 0.5 µg/ml gentamicin and 2.5 µg/ml 
amphotericin B. EEB cell line and EEB-aneuploid clones were cultured with StemSpan SFEM medium 
supplemented with 15% FBS. 
3.1.3 Cryopreservation of cells 
Cells were resuspended in FBS with 10% DMSO at a concentration of 5-8*10
6
 cells/ml and transferred 
to cryovials. Cryovials were stored at -80°C overnight and then moved to liquid nitrogen for long-
term storage. 
3.1.4 Aneuploid cell enrichment 
To enrich for aneuploid cells, EEB cells were synchronized at G1/S phase transition by thymidine 
treatment (2 mM) for 24 hours. After thymidine washout the cells were treated with 50 nM CENP-E 
inhibitor (GSK923295) and 480 nM MPS1 inhibitor (NMS-P715) for 24 hours and single seeded in 96-
well plates. 
3.1.5 Single cell cloning by limited dilution of suspension cells 
Single cells were seeded in 96-well plates. 1.25*10
5
 cells were diluted in 500 µl of medium, 50 µl 
were added to 950 µl of medium, 10 µl were transferred in 20 ml and 200µl were plated in each well. 
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3.1.6 Cell growth curves  
Cell growth was evaluated by trypan blue exclusion with TC10 Trypan Blue Dye 0.4%. Cells were 
counted at 24 hours intervals with TC20™ automated cell counter. 
3.1.7 Drug-response curves 
1*10
4 
primary cells per well with 25 µl medium were seeded at day zero in 384-well plates. Cells 
were treated after 24 hours with the addition of the drug in 25 µl medium. All experiments were 
carried out in triplicate. Cell viability was measured after 72 hours of treatment with an ATP-based 
detection system, the CellTiter-Glo® 2.0 Assay, according to manufacturer´s instructions. 
Luminescence was measured with Spark microplate reader. 
2*10
5 
cells per well were seeded in 96-well plates with 100 µl of medium to which the compounds 
were added. All experiments were carried out in triplicate. Cell viability was measured after 48 hours 
of treatment, following the addition of the WST-1 reagent, according to manufacturer´s instructions. 
Absorbance was measured with Spark microplate reader. 
3.1.8 Cell cycle analysis 
1*10
6
 cells were collected and resuspended in 250 µl 1x PBS. Cells were fixed with dropwise addition 
of 700 µl of ice-cold 100% methanol and stored at 4°C for at least 1 hour. Samples were centrifuged 
at 350 rcf, washed with 10 ml 1x PBS and stained with 200 µl of working solution (propidium iodide 
(stock 1 mg/ml, 1:100) with the addition of RNase A (stock 10 mg/ml, 1:40)) for at least 30 minutes in 
the dark. Cells were acquired with Accuri C6 flow cytometer and cell cycle was analyzed with BD 
Accuri C6 software. 
3.1.9 Caspase activity assay 
Cells were seeded at day zero in 384-well plates and treated with the compound of interest after 24 
hours. All experiments were carried out in triplicate. Caspase activity was measured with a 
luminescent assay, the Caspase-Glo® 3/7 Assay according to manufacturer´s instructions. 
Luminescence was measured with Spark microplate reader. 
3.1.10 Apoptosis assay 
Apoptotic cells were detected with the FITC Annexin V Apoptosis Detection Kit 1 according to 
manufacturer´s instructions. Samples were analyzed with Accuri C6 flow cytometer. 
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3.1.11 Immunofluorescence staining 
4*10
5
 cells were cytospun on slides and fixed with either ice-cold methanol/acetone (1:1) for 7 
minutes or 4% PFA for 10 minutes according to the antibodies used. Cells were permeabilized with 
0.2% tryton for 5 minutes, washed once with 1x PBS, blocked in 10% goat serum in 1x PBS for 30 
minutes and incubated with primary antibodies for 1 hour. Following the primary antibody 
incubation, the cells were washed three times for 5 minutes in 1x PBS and incubated for 30 minutes 
with appropriate species-specific secondary antibodies. DNA was counterstained with Hoechst 33342 
diluted 1:1000 in 1x PBS for 5 minutes. The slides where washed three times with 1x PBS and once 
with double distilled water. Coverslips were mounted in Vectashield antifade mounting medium and 
were analyzed by fluorescence microscopy on a Zeiss Cell Observer.Z1 system equipped with an 
AxioCam MRm camera, or an Axioskop equipped with an AxioCam MRm camera. For image analysis 
the software ZEN lite 2011 was used. 
3.1.12 Metaphase spreads 
Confluent cells were treated with 10 μg/ml colcemid for 1 hour at 37°C followed by centrifugation at 
280 rcf for 10 minutes. Hypotonic treatment of the samples with pre-warmed to 37°C 0.075 M KCl 
was performed and samples were incubated for 10 minutes at 37°C. Cells were fixed by dropwise 
addition of ice-cold methanol/glacial acetic acid (3:1) and centrifuged for 10 minutes at 280 rcf. 
Three additional steps of fixation followed. Cells were dropped on glass slides from a height of about 
30 cm; slides were dried at 56°C, stained with Hoechst 33342 and mounted in Fluoromount-G™ or 
prepared for whole chromosome multiplex fluorescence in situ hybridization (M-FISH). Control of 
mitotic index (1-2 mitoses/field) was performed at bright field microscope (20X objective). Samples 
were stored at -20°C. 
3.1.13 Multiplex fluorescence in situ hybridization and karyotyping 
M-FISH and karyotyping were performed by Brigitte Schoell and Prof. Dr. Anna Jauch, Institute of 
Human Genetics, University Hospital Heidelberg. 
3.1.14 Evaluation of surface markers 
The evaluation of surface markers by flow cytometry was performed at the Department of Internal 
Medicine V, University Hospital Heidelberg. 
3.1.15 Transfection with plasmids 
For transfection of plasmids the Neon™ Transfection System was used. One day prior to 
electroporation the cells were transferred into a flask with fresh medium. 24-well plates were 
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prepared by filling the wells with 500 µl of medium and kept in a humidified 37°C/5% CO2 incubator. 
2.5*10
5
 cells per well were used; they were washed with 1x PBS and resuspended in 10 µl Buffer R. 1 
µl plasmid DNA was transferred to a 1.5 ml microcentrifuge tube, cells were added to it and gently 
mixed. A Neon™ Transfection Tube was filled with 3 ml Electrolytic Buffer E into the Neon™ Pipette 
station. The DNA/cells mixture was aspirated with the Neon™ Pipette with a 10 µl Neon™ Tip. The 
Neon™ Pipette was inserted into the Neon™ Transfection Tube placed in the Neon™ Pipette Station. 
Cells were electroporated with 1200 mV or 1350 mV, pulse width 35, pulse 1 and finally transferred 
to a well.  
3.1.16 Selection of transfected cells 
Transfected cells were selected 72 hours after electroporation. Cells were treated with 2 µM 
puromycin for 7 days. Puromycin was added freshly every 2 days.    
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3.2 Protein biochemistry methods  
3.2.1 Cell lysates and determination of protein concentration  
Cells where collected and washed with ice-cold 1x PBS. RIPA buffer was added to the cell pellet and 
samples were incubated on ice for 30 minutes with frequent vortexing. Samples were centrifuged for 
10 minutes at 18000 rcf at 4°C and the supernatant was transferred into precooled tubes. 
To determine the protein concentration of the lysates the Bradford assay was used. 1 ml dye reagent 
for the Quick Start™ Bradford Protein Assay and 1 μL of the protein lysate were mixed and incubated 
for 5 minutes. Absorbance at 595 nm was measured by spectrophotometry. To create a calibration 
curve BSA standard was used. Cell lysates were mixed with 1x SDS protein loading buffer and boiled 
for 5 minutes at 95 °C. Samples were directly used or stored at -80°C. 
3.2.2 Gel electrophoresis 
The electrophoretic separation of proteins was performed under denaturing conditions. Gels with 6-
15% acrylamide gels, depending on the size of the proteins to be detected, were prepared following 
Thomas and Kornberg protocol
101
. 20-50 µg of proteins were loaded for each well. The separation 
was performed at 90 V for 2 hours. 
3.2.3 Western blot analysis and immunodetection 
Separated proteins were transferred to an Immun-Blot® PVDF membrane by semi-dry transfer 
method using Trans-Blot® Turbo™ System. The membrane was activated in 100% ethanol for one 
minute and sandwiched with the gel between Trans-Blot® Turbo™ Midi Size Transfer Stacks, soaked 
in 1x transfer buffer (5x Trans-Blot® Turbo™ 100 ml, ethanol 200 ml, ddH2O 700 ml). Protein transfer 
was performed for 10 minutes for the transfer of high molecular weight proteins according to the 
manufacturer’s instructions. The proteins were then detected by immunodetection.  
For the detection of proteins by means of immunodetection the membrane was blocked for one 
hour with 5% of either milk powder or BSA in 1x TBS-T at room temperature and then incubated with 
the primary antibody overnight at 4°C with gentle shaking. After three 5-minute washes with 1x TBS-
T, the membrane was incubated with the secondary antibody for 1 hour at room temperature and 
then again washed three times for 5 minutes each with 1x TBS-T. Both primary and secondary 
antibodies were diluted in either 5% milk powder or 5% BSA in 1x TBS-T. Detection was done by 
incubating the membrane for 5 minutes with Clarity™ Western Blotting ECL Substrate followed by 
chemoluminescence signal detection with ChemiDoc™ Touch Imaging System following 
manufacturer’s instructions. Image analysis was performed with the Image Lab software. 
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3.3 Molecular biology methods 
3.3.1 DNA extraction 
DNA extraction was performed using QIAmp DNA Mini Kit following manufacturer’s specifications. 
DNA concentration and purity was measured at 260nm/280nm with a NanoDrop 2000 
Spectrophotometer. 
3.3.2 RNA extraction 
Total RNA extraction was performed using RNeasy Mini Kit following manufacturer’s specifications. 
RNA was subjected to DNAse I treatment. RNA concentration and purity were measured with a Qubit 
fluorometer. 
3.3.3 Polymerase chain reaction (PCR) 
To amplify regions of interest of genomic DNA, a polymerase chain reaction (PCR) was performed 
using either Phusion® High-Fidelity DNA Polymerase or CloneAmp™ HiFi PCR Premix, following 
manufacturer´s protocol. 
3.3.4 Agarose gel electrophoresis 
For analysis and quality control purposes, size separation of DNA and RNA fragments by agarose gel 
electrophoresis was performed.  
For DNA samples, 1% agarose gels were prepared and supplemented with 0.1 μL/mL ethidium-
bromide. Samples were mixed with 6x loading dye and were run in an electrophoresis chamber filled 
with 1x TAE buffer for 40 minutes at 110 V.  
Isolated RNA samples were mixed 1:1 with RNA Sample Loading buffer, added to 8 µl of nuclease-
free water and cooked at 65°C for 10 minutes. Samples were run in an electrophoresis chamber with 
1x MOPS buffer for 1 hour at 80 V.  
Both DNA and RNA separated bands were visualized by UV light in a gel documentation system. 
3.3.5 RNA sequencing 
50 µl of 40 ng/µl RNA of each sample with RIN values >8 were prepared and sent for processing to 
the Core Facility Genomics and Proteomics, DKFZ. Each sample was sent in biological triplicate. 
Libraries were made with TruSeq Stranded mRNA Prep Kit (Illumina). 100bp paired-end sequencing 
was carried out on an Illumina HiSeq 4000 sequencing system. The resulting reads were analyzed by 
Mahmoud Abdelrahman, Division of Applied Bioinformatics, DKFZ. Data were also analyzed through 
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the use of QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity) in order to evaluate most significant canonical pathways across the 
dataset and predict upstream regulators that could account for the possible gene expression 
differences. The z-scores determine whether a pathway or an upstream transcriptional regulator is 
predicted to be significantly activated (z>0) or inhibited (z<0). p values were calculated using Fisher’s 
exact test. 
3.3.6 sgRNA design 
Four sgRNA targeting the human TP53 were designed using the CRISPOR tool which predicts, among 
many scores, the specificity score and the off-target count. sgRNA were chosen among those with 
the highest specificity score and the lowest off-target count. 
3.3.7 sgRNA testing 
The guide RNAs used for the CRISPR/Cas9 genome editing were tested with the Guide-it™ sgRNA In 
Vitro Transcription and Screening Systems according to the manufacturer’s instructions. 
3.3.8 Plasmid digestion 
2-3 µg of plasmids were digested with proper restriction enzymes according to manufacturer´s 
instructions. Dephosphorylation with 2 µl Shrimp Alkaline Phosphatase (SAP) for 30 minutes 
followed. 5 µl of the digested plasmids were loaded on an agarose gel to assess the digestion of the 
vectors. Digested plasmids were purified with High Pure PCR Product Purification Kit according to 
manufacturer´s instructions. 
3.3.9 Annealing and phosphorylation of oligonucleotides 
For each sgRNA 100 nM of the top strand and 100 nM of the bottom strand of oligonucleotides were 
annealed in a thermocycler: the lid temperature was set at 99°C, samples were incubated for 5 
minutes at 95°C, and then the temperature was gradually reduced by 0.1°C/second up to 25°C and 
maintained at 25°C for 5 more minutes. 
The annealed oligos were phosphorylated for 30 minutes at 37°C (16 µl annealed oligos, 2 µl 10x T4 
Polynucleotide Kinase Reaction Buffer (PNK buffer), 1 µl T4 Polynucleotide Kinase, 1 µl ATP 10 mM). 
The reaction was inactivated at 65°C for 15 minutes. 
3.3.10 Ligation 
8 µl of vector, 8 µl of annealed and phosphorylated oligos, 2 µl ligase buffer, 0.5 µl 10 mM ATP and 1 
µl ligase were incubated at room temperature for 30 minutes. The ligation process was inactivated 
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incubating the samples at 70°C for 15 minutes. The ligated product was diluted 1:5 in nuclease-free 
water. 
3.3.11 Heat shock transformation of bacteria  
To amplify DNA constructs, the replication system of E. Coli was exploited. Transformation of 
competent E. Coli DH5α strain F
-
 φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17(rK
-
, mK
+
) 
phoA supE44 thi-1 gyrA96 relA1 λ
-
 bacteria was accomplished by heat shock transformation. Frozen 
aliquots of E. Coli DH5α strain were thawed on ice and 100 μL of competent bacteria were added to 5 
μL of plasmid DNA. The mixture was then incubated on ice for 30 minutes. Heat shock 
transformation was performed for 45 seconds at 42°C, quickly followed by 2 minutes incubation on 
ice. Transformed bacteria were then transferred to 900 μL of SOB medium freshly supplemented 
with 20 mM glucose (SOC medium), without antibiotics, and incubated for 1 hour at 37°C under 
shaking. Bacteria were pelleted by centrifugation for 5 minutes at 350 rcf, resuspended in about 100 
μL of SOC medium and plated at different dilutions on LB-agar supplemented with an appropriate 
selection antibiotic. Bacteria colonies grew overnight in a 37°C incubator. 
3.3.12 Isolation of plasmid DNA  
Transformed bacteria colonies were isolated and transferred to liquid cultures in LB-medium. 
Bacteria were selected under appropriate antibiotics. To obtain small amounts of plasmid, 3 ml of 
liquid culture were incubated overnight at 37°C under shaking. Plasmid DNA was purified from small 
liquid culture using QIAprep Spin Miniprep Kit according to manufacturer’s instruction.  
For larger amounts of DNA, following this first step, the purified plasmid was retransformed. 10 ml of 
liquid culture were finally incubated for about 4-5 hours at 37°C under shaking and then transferred 
to 100 ml of liquid culture and incubated overnight at 37°C under shaking. Plasmid DNA was purified 
from larger cultures with the QIAGEN Plasmid Maxi Kit. Concentration of the obtained DNA was 
determined using a NanoDrop 2000 spectrophotometer at 260nm/280nm. 
3.3.13 PCR product and plasmid DNA sequencing 
Samples were sent to GATC for Sanger sequencing. PCR products and plasmids were diluted in 20 µl 
to a concentration of 10-50 ng/µl and 30-100 ng/µl, respectively. Primers were diluted in 20 µl at a 
concentration of 100 pmol/µl. 
3.4 Statistical analysis 
Data were analyzed in Prism 7 (GraphPad Software, La Jolla, California, USA, www.graphpad.com).
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4 Results 
4.1 Identification of compounds that inhibit the proliferation of aneuploid AML cells 
4.1.1 Drug screening in AML patient samples 
14 compounds (Tab. 27) were screened in AML patient samples with both normal and complex 
karyotypes, thereby comparing euploid versus aneuploid karyotype AML cell response. Standard 
anticancer drugs and compounds with proposed selective efficacy against aneuploid cells identified 
in non-hematopoietic cell types were included in the screen
61,74,77
. In detail, 8-azaguanine, 17-AAG, 
AICAR, ASA, chloroquine, metformin and resveratrol were tested. Conventional chemotherapeutic 
drugs cytarabine and daunorubicin, which are used in daily practice for AML treatment, were also 
included in the analysis. Agents interfering with the mitotic spindle such as taxol and vincristine and 
the alkylating agent cisplatin were tested as well. Since PLK4 drives centrosome replication, which is 
responsible for the set-up of the normal bipolar mitotic spindle apparatus and the correct 
distribution of chromosomes into the two daughter cells, the polo-like kinase 4 (PLK4) inhibitor 
centrinone was also included in the panel. The effect of crenolanib, recently described as a 
centrosome clustering inhibitor
102
 was evaluated as well. At least in theory, aneuploid AML cells with 
centrosome amplification might be vulnerable to the latter two compounds
44
.  
 
Compound Group Rationale 
8-Azaguanine Purine analogue Potentially aneuploidy-selective 
17-AAG 
(17-Allylamino-geldanamycin) 
Geldanamycin analogue 
- Potentially aneuploidy-selective 
- HSP90 inhibitor 
AICAR 
(5-Aminoimidazole-4-
carboxamide ribonucleotide) 
AMP analogue 
- Potentially aneuploidy-selective 
- Stimulates AMPK and mimics  
   energy stress 
ASA  
(Acetylsalicylic acid) 
Salicylate 
- Potentially aneuploidy-selective 
- Stimulates AMPK 
Centrinone PLK4 inhibitor Mitotic spindle interference 
Chloroquine Chinine analogue 
- Potentially aneuploidy-selective 
- Inhibits autophagy 
Cisplatin Platin 
- Cytostatic drug 
- Alkylating agent 
Cytarabine 
(Cytosine arabinoside, Ara-C) 
Arabinosyl nucleoside 
- AML standard cytostatic drug 
- Antimetabolite 
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Crenolanib FLT3 inhibitor Centrosome clustering inhibitor 
Daunorubicin Anthracycline 
- AML standard cytostatic drug 
- Topoisomerase II inhibitor 
Metformin Biguanide 
- Potentially aneuploidy-selective 
- Activates AMPK and induces  
   energy stress 
Resveratrol Phytoalexine 
- Potentially aneuploidy-selective 
- Stimulates AMPK 
Taxol Taxane 
- Cytostatic drug 
- Mitotic spindle interference 
Vincristine Vinca alkaloid 
- Cytostatic drug 
- Mitotic spindle interference 
 
 
Table 27 | Compounds screened in AML primary samples 
4.1.2 8-Azaguanine selectivity against aneuploid primary AML samples 
Primary AML samples with a euploid karyotype and  with an aneuploid karyotype were treated for 72 
hours with the above mentioned compounds at increasing concentrations (Fig. 4; Fig. S1). It is worth 
noting that all the samples included in the study were characterized by the presence of at least 80% 
of blasts. Euploid samples harbored a normal karyotype with the exception of three of them, which 
harbored few structural aberrations (Tab. S1); those with an aneuploid karyotype, harbored 
numerical aneuploidies and, with the exception of one, a complex karyotype (Tab. S2). Samples with 
aberrations which are considered to lead to a favorable prognosis were excluded from the analysis. 
Among all drugs tested, only 8-azaguanine was identified as more effective against aneuploid AML 
samples (Fig. 4A). Primary samples harboring three or more numerical aneuploidies (chromosome 
rearrangements were not considered in the analysis) were most responsive to the compound at high 
concentrations (Fig. 4B). This result suggests that the efficacy of 8-azaguanine may be influenced by 
the degree of aneuploidy, independent of the preponderance of chromosome gains or losses. 
8-Azaguanine is a purine analogue. As other nucleoside analogues, it becomes active after 
phosphorylation to its triphosphate derivative and competes with endogenous nucleosides. Besides 
being incorporated into nucleic acids and thus affecting their structural integrity, nucleoside 
analogues can also interact with different enzymes, such as those involved in nucleotide metabolism, 
interfering with their active sites. Although nucleoside analogues share common structural features 
and traits of their mechanisms of action, they also display unique aspects. 8-Azaguanine has been 
described to be incorporated in both DNA and RNA, thereby inhibiting cell growth. It has been 
additionally demonstrated that its toxicity is mainly due to its incorporation into RNA
103
. The 
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compound has been shown to hinder the protein synthesis machinery and interfere with the 
initiation of translation in mouse chronic lymphocytic leukemia cells
104
. 8-Azaguanine has potential 
antineoplastic activity. Indeed, its efficacy against transplanted mouse adenocarcinomas, 
spontaneous tumors in mice and human high-ploidy breast cancer cells in vitro has already been 
demonstrated
105,77
. On the other hand, a subset of mouse and rat tumors such as sarcomas and 
carcinomas did not respond to the compound
105
. Moreover, an early clinical study reported a positive 
response of three AML patients treated with the drug
106
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 | 8-Azaguanine is selectively active against aneuploid primary AML samples 
 
(A) Cell viability after 72 hours of treatment with 8-azaguanine. The graph shows means ± 95% CI. 
Statistical significances of the differences between euploid versus aneuploid AML samples treated 
with 8-azaguanine for AUC (area under the curve) and IC50 (inhibitory concentration 50%) are p=0.02 
and p=0.008, respectively. (B) The aneuploid group was divided in two subgroups according to the 
number of numerical chromosome changes (≤2, ≥3), including both whole chromosome gains and 
losses. 
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4.2 Generation of EEB-derived cell lines differing in ploidy 
The comparison between otherwise isogenic euploid and aneuploid AML cells is hampered by the 
lack of euploid AML cell lines. Leukemia cell lines are difficult to establish as AML primary cells are 
normally hard to grow in culture. To our knowledge, only three AML cell lines have been described as 
euploid in the literature
107,108,109
. Among them, the EEB cell line
108
, which was established from a 
patient with early erythoblastic leukemia with 80% of blast carrying a normal karyotype, was the one 
which was efficiently growing in our hands. To reduce the variability among different cell lines, an 
isogenic AML cell model was established. We generated isogenic aneuploid clones which derive from 
the euploid AML cell line EEB and share a common genetic background but display aneuploidy to 
different degrees.   
4.2.1 EEB cell line single seeding 
Analysis of the EEB cell karyotype revealed a low level of aneuploidy. After single cell seeding three 
different clones were isolated: a clone with a normal diploid karyotype (46, XY) (relative frequency 
within the parental EEB cell line: 81%) (Fig. 5A-a), a subclone with loss of chromosome Y (45, X, -Y) 
(relative frequency within the parental EEB cell line: 17%) (Fig. 5A-b), and a subclone with a near-
tetraploid karyotype with loss of both Y chromosomes (90, XX, -Y, -Y) (relative frequency within the 
parental EEB cell line: 2%) (Fig. 5A-c). The karyotypes of these clones were verified by M-FISH (Fig. 
5A). 
4.2.2 Generation of de novo aneuploidies 
With the aim of expanding the model and obtaining additional clones we induced de novo 
aneuploidies by treating parental EEB cells with a combination of a CENP-E and a MPS1 inhibitor 
(NMS-P715 and GSK923295, respectively) for 24 hours, after 24 hours of thymidine G1/S 
synchronization.  
Centromere-associated protein-E (CENP-E) is a 312 kDa kinesin-like motor protein which contributes 
in generation and maintenance of chromosome-microtubule interactions and is involved in 
chromosome alignment by moving chromosomes from the spindle poles to the metaphase 
plate
110,111
. It accumulates in late G2 and is degraded at the end of mitosis
112
. Multipolar spindle-1 
(MPS1) is a protein kinase and core element of the SAC
31
. With CENP-E and MPS1 inhibition 
chromosomes are retained at the spindle poles and the SAC is inactivated. It has previously been 
shown that combining a CENP-E inhibitor (CENP-Ei) and low doses of a MPS1 inhibitor (MPS1i) results 
in chromosome missegregation without inducing any mitotic delay
113
. 
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After treatment with the inhibitors and subsequent single cell seeding, three additional clones with 
trisomy 7 and 21 (47, X, -Y, +7, +21), trisomy 12 (47, XY, +12) and trisomy 22 (47, XY, +22), 
respectively, were isolated. The karyotypes of these clones were also verified by M-FISH (Fig. 5B). 
Clones with de novo aneuploidies were generated in collaboration with Ilka Jansen. 
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Figure 5 | Clones derived from the AML EEB cell line 
 
(A) Karyotypes of euploid (46, XY) (a), hypodiploid (45, X, -Y) (b) and near-tetraploid (90, XX, -Y, -Y) (c) 
EEB cells isolated after EEB single cell seeding, as determined by M-FISH analysis. (B) Karyotypes of 
double-trisomic (47, X, -Y, +7, +21) (a) and two trisomic (47, XY, +12) (b) (47, XY, +22) (c) clones 
generated after treatment with MPS1 and CENP-E inhibitors, as determined by M-FISH analysis. 
4.2.3 Generation of p53 knock-out clones 
Aneuploidy has been described to trigger p53 activation, limiting cell growth. However, the 
mechanisms which link chromosome aberrations to p53 activation remain not completely 
understood. It is still uncertain whether p53 is activated by mere aneuploidy or whether its activity is 
triggered by other conditions associated with chromosome missegregation. Thompson and Compton 
proposed that chromosome missegregation per se can activate p53 through p38 activation, without 
evidence of DNA damage
68
. On the other hand, another group observed that chromosome 
segregation errors cause at first DNA damage and subsequently the activation of ataxia-telangectasia 
mutated (ATM) and p53
65
. Along the same lines, a study reported elevated levels of reactive oxygen 
species (ROS) after chromosome missegregation, which subsequently induce oxidative DNA damage, 
ATM and p53 activation
69
. More recent work has demonstrated that aneuploid cells with complex 
aberrations show replication stress, DNA damage and p53 activation, followed by innate immune 
response
114
. 
Since p53 might therefore hamper the generation of aneuploid EEB clones by limiting aneuploid cell 
proliferation, we performed a CRISPR/CAS9-mediated TP53 knock-out in order to generate additional 
aneuploid EEB clones and to eventually evaluate drug response in a p53 knock-out setting. Three 
independent p53 knock-out EEB-derived cell lines were generated from the euploid clone (Fig. 6). 
p53 knock-out cell lines were established in collaboration with Christin Schlegel. 
The karyotypes of the p53 knock-out cell lines were also verified by M-FISH. Besides differing from 
the previously generated clones with regard to their p53 status, they presented widespread 
karyotypic heterogeneity, with cells harboring both numerical and structural abnormalities (Fig. 7). 
Within the cell line 10-1 no predominant aberrant clone could be detected. Line 9-5 showed two 
main aberrant clones (relative frequencies within 20 metaphases: both 30%) with other additional 
abnormalities in the remaining metaphases. The clone 8-1 mainly consisted of near-tetraploid cells, 
with the exception of one metaphase which was near triploid, both harboring several additional 
aberrations that lead to a complex clonal heterogeneity. 
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Figure 6 | Sanger sequencing and Western blot confirming CRISPR-induced p53 knock-out 
 
(A) Confirmation of p53 mutation (arrow – deletion C) and knock-out (cell line 10-1). (B) 
Confirmation of p53 mutation (arrow – insertion G/A) and knock-out (cell line 9-5). (B) Confirmation 
of p53 mutation (deletion of 940 base pairs) and knock-out (cell line 8-1). wt: wild-type; ko: knock-
out. 
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Figure 7 | Karyotypic heterogeneity of the p53 knock-out EEB-derived cell lines 
 
(A) Cell line 10-1. (B) Cell line 9-5. (C) Cell line 8-1. Each row represents a metaphase. In addition to 
the depicted aneuploidies, some cells also harbored structural rearrangements (alteration of 
chromosome structure (Fig. 8)). 
4.2.3.1 p53 deficiency allows for extensive karyotypic heterogeneity and propagation of structural 
aneuploidies and rearrangements in AML EEB cells 
The link between p53 activation/deficiency and aneuploidy propagation is still a matter of discussion. 
It has been described that p53 deficiency alone is not sufficient to cause aneuploidy and CIN, but 
additional stimuli that trigger chromosome segregation errors need to occur
115,68
. It is still unclear 
whether aneuploidy per se can be sensed by p53. Untransformed RPE-1 p53 wild-type cells have 
been described to still actively proliferate in presence of numerical aneuploidies
113,114
 and aneuploid 
MEFs do not show elevated p53 levels
61
. On the contrary, it has been reported that chromosome 
missegregation induces p53-dependent cell cycle arrest in HCT116 and RPE-1 cells
68
.  
The p53 knock-out cells we generated harbored several non-clonal chromosomal abnormalities. 
Thus, with the two purposes of investigating whether p53 disruption alone causes aneuploidy/CIN 
and further evaluating which type of chromosomal abnormalities, if any, can be propagated in p53-
proficient versus p53-deficient cells, we single seeded p53 wild-type and p53 knock-out cells (cell line 
10-1 (Fig.7A)). For each condition, we evaluated karyotypes from 20 cells of 6 subclones by M-FISH, 
C 
A 
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for a total of 120 cells for each setting. M-FISH analysis showed that a subset of untreated p53 wild-
type EEB cells harbored a loss of chromosome Y, which we considered as a spontaneous 
characteristic event of the cell line. For this reason we did not score the loss of chromosome Y in our 
analysis. For the purpose of this study, with numerical aneuploidy we refer to gains or losses of entire 
chromosomes and with structural aneuploidy to gains or losses of sub-chromosomal regions. The 
term structural rearrangement instead refers to alterations of chromosome structure including 
telomere associations, Robertsonian translocations, isochromosomes, ring chromosomes, 
translocations and derivative chromosomes (Fig. 8). Since M-FISH was performed for the evaluation 
of chromosome aneuploidies and this technique allows for the evaluation of chromosome structural 
rearrangements, I decided to additionally include this category in our analysis.  
 
Figure 8 | Numerical aneuploidy, structural aneuploidy and structural rearrangement 
 
Numerical aneuploidy: chromosome loss (left), chromosome gain (right). Structural aneuploidy: sub-
chromosomal region loss (left), sub-chromosomal region gain (center and right). Structural 
rearrangement: unbalanced translocation (left), telomere association (center), chromosome ring and 
balanced translocation (right). 
M-FISH analysis revealed that p53 knock-out led to a significantly higher number of cells with 
numerical aneuploidies in comparison to p53 wild-type cells (17% and 4%, respectively; p=0.02), and 
that a fraction of p53 knock-out cells harbored structural aneuploidies (10%), whereas p53 wild-type 
cells did not (p=0.06)(Fig. 9A-B). These data demonstrate that p53-deficient compared to p53-
proficent cells can spontaneously acquire and propagate numerical aneuploidies and structural 
aneuploidies, even if this last difference failed to achieve statistical significance probably because of 
the small sample size. 
We then treated both p53-proficient and p53-deficient cells with CENP-E and MPS1 inhibitors with 
the purpose to trigger de novo chromosome missegregation. We single seeded the treated cells and 
evaluated for each condition the karyotype from 20 cells of 6 subclones, for a total of 120 cells for 
each setting. In the case of p53 wild-type clones, the number of cells with numerical aneuploidy 
increased significantly in comparison to the respective untreated clones (18% vs 4%), but only few 
structural aneuploidies developed (3%). On the other hand, p53 knock-out clones treated with the 
inhibitors not only acquired a significantly higher amount of cells harboring numerical aneuploidies 
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compared to untreated clones (43% vs 17%), but also a large fraction with structural aneuploidies 
(27%) (Fig. 9A-B). The comparison between treated p53-proficient and p53-deficient cells showed a 
significant difference in the level of numerical aneuploidy (p=0.01) and the difference in the level of 
structural aneuploidy almost reached statistical significance (p=0.069). Once more these data suggest 
that p53 deficiency allows tolerance for at least numerical aneuploidies. 
Considering structural rearrangements, they were not found in untreated p53-proficient cells and 
only few (6% of cells) appeared after the induction of chromosome missegregation by CENP-Ei and 
MPS1i. On the contrary, 9% of p53-deficient cells already spontaneously harbored structural 
rearrangements (p=0.02), which increased to 45% after the induction of chromosome missegregation 
(treated p53-proficient vs treated p53-deficient cells p=0.004) (Fig. 9C).  
These results suggest that numerical aneuploidies are well tolerated by p53 wild-type AML EEB cells, 
whereas the presence of p53 limits the propagation of structural aneuploidies and structural 
rearrangements almost completely. While DNA damage could not be detected in p53-proficient cells, 
p53-deficient cells showed Western blot positivity for ɣ-H2AX, a marker of damaged DNA. This 
suggests that DNA damage occurring during the generation of structural aneuploidies and structural 
rearrangements may cause a p53-mediated cell cycle arrest and cell death, thus limiting the 
propagation of structural abnormalities to p53 knock-out cells (Fig. 9D). 
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Figure 9 | p53 limits the propagation of structural aneuploidies and rearrangements 
 
(A) Percentage of cells either expressing p53 or not, harboring numerical aneuploidies before and 
after the induction of segregation errors with CENP-E and MPS1 inhibitors (+i). (B) Percentage of cells 
either expressing p53 or not, harboring structural aneuploidies before and after the induction of 
segregation errors with CENP-E and MPS1 inhibitors (+i). (C) Percentage of cells either expressing p53 
or not, harboring structural rearrangements before and after the induction of segregation errors with 
CENP-E and MPS1 inhibitors (+i). (D) DNA damage in p53 knock-out cells as detected by 
immunoblotting with an antibody to ɣ-H2AX. Actin served as a loading control. wt: wild-type; ko: 
knock-out. 
In order to gain insight into the level of CIN of p53-proficient and p53-deficient AML EEB cells before 
and after the induction of segregation errors, we evaluated the CIN-index of every chromosome in 20 
cells of 6 subclones for each setting (p53 wild-type, p53 wild-type + CENP-Ei/MPS1i, p53 knock-out, 
p53 knock-out + CENP-Ei/MPS1i), considering both numerical and structural aneuploidies
116,117
. The 
numerical CIN-index was defined as follows: for each chromosome the number of cells that deviated 
from the modal chromosome number of 2 was counted and then divided by the number of cells 
analyzed. The structural CIN-index was defined considering for each chromosome the number of cells 
that harbored a structural aneuploidy, then dividing this count by the number of cells analyzed. The 
average numerical CIN-index was obtained excluding chromosome Y, whereas the average structural 
CIN-index was calculated considering all chromosomes, including chromosome Y. While p53-
proficient cells spontaneously did almost not display any deviation from the modal chromosome 
number and normal structure (max numerical CIN-index 5%; structural CIN-index 0%), p53-proficient 
cells after the induction of chromosome missegregation and p53-deficient cells both with and 
without addition of missegregation stimuli deviated from the modal chromosome number and 
normal structure (max numerical CIN-index: 10%, 20%, 35%, respectively; max structural CIN-index: 
5%, 10%, 100%, respectively). The average numerical CIN-index for p53 wild-type cells before and 
after induction of chromosome missegregation was 0.3% and 1.7%, respectively; their average 
structural CIN-index before and after treatment with CENP-Ei and MPS1i was 0% and 0.3%, 
respectively (Fig. 10). The average numerical CIN-index for p53 knock-out cells before and after 
induction of chromosome segregation errors was 4.4% and 5.4%, respectively; their average 
structural CIN-index before and after treatment with CENP-Ei and MPS1i was 0.5% and 5.2%, 
respectively (Fig. 10). 
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Figure 10 | p53 knock-out allows for chromosomal instability 
 
Average numerical CIN (N-CIN) and average structural CIN (S-CIN) indices in p53-proficient and p53-
deficient cells before and after induction of chromosome missegregation with CENP-E and MPS1 
inhibitors (+i). Error bars show SEM. wt: wild-type; ko: knock-out. 
Importantly, chromosome alterations (numerical and structural aneuploidies and structural 
rearrangements) obtained after p53 knock-out and also after the induction of chromosome 
missegregation were not clonal and varied largely from cell to cell (Fig. 11, Fig. S2). Only some cells 
harbored common chromosome alterations suggesting that they evolved from the same ancestor, 
but had acquired additional alterations on their own, which made them to differ from each other.  
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Figure 11 | p53 deficiency allows for karyotypic heterogeneity  
 
Schematic representation of karyotypes considering 20 metaphases of one representative clone for 
each category (from top to bottom: p53 wild-type (wt), p53 wild-type treated with CENP-Ei and 
MPS1i (wt+i), p53 knock-out (ko) and p53 knock-out treated with CENP-Ei and MPS1i (ko+i)). Each 
row represents a metaphase. The presence of at least one chromosome with structural 
rearrangement in addition to aneuploidy is depicted with double color.  
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4.3 Evaluation of the influence of aneuploidy on cellular fitness 
Aneuploidy has been described to limit cell proliferation under normal growth conditions. In our 
model the euploid and the hypo-/hyperdiploid p53 wild-type clones showed similar growth rates. 
This probably reflects the low level of chromosome abnormalities of these clones. Indeed, only the 
near-tetraploid clone showed a slower rate of proliferation (Fig. 12).  
 
Figure 12 | Low levels of aneuploidy do not impair cell growth in p53-wild-type AML EEB cells 
 
Growth curves of euploid and aneuploid p53-wild-type clones. 
4.4 8-Azaguanine selectivity against aneuploid AML EEB clones 
In order to confirm the observations made in primary AML samples, AML EEB-derived p53 wild-type 
clones, including the euploid clone (46, XY), the double-trisomic (47, X, -Y, +7,+21), the two trisomic 
clones (47, XY, +12; 47, X, Y, +22), the hypodiploid clone (45, X, -Y) and the near-tetraploid clone (90, 
XX, -Y, -Y) were exposed to increasing concentrations of 8-azaguanine. 
As shown by the viability assay, three aneuploid clones (the hypodiploid (45, X, -Y), the double-
trisomic (47, X, -Y, +7, +21) and the near-tetraploid (90, XX, -Y, -Y)), when compared to the euploid 
clone, responded better to the compound after 48 hours of treatment at concentrations of 1.25 and 
2.5 µM (Fig. 13A). From here on these three aneuploid clones will be addressed as “responder 
aneuploid clones”. On the other hand, the two trisomic clones (47, XY, +12 and 47, XY, +22) showed 
lower responsiveness to the drug (“non-responder aneuploid clones”). These results were confirmed 
by an apoptosis assay after treatment with 1.25 µM 8-azaguanine for 48 and 72 hours. Indeed, at the 
48 hour time point, while only 23.3 ± 10.4% of the euploid cells were undergoing apoptosis, 37.5 ± 
5.2% of the hypodiploid (p=0.029), 42.6 ± 5.5% of the double-trisomic (p<0.001) and 58.6 ± 6.5% of 
the near-tetraploid (p<0.001) cells were apoptotic (Fig. 13B).  
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8-Azaguanine was also tested in the p53 knock-out cell lines. The percentage of apoptotic cells was 
significantly higher in two out of three of the p53 knock-out cell lines compared to the euploid p53 
wild type clone (Fig. 13C). The p53 knock-out cell line 10-1, which does not efficiently respond to 8-
azaguanine treatment, harbors low CIN levels as compared to the other two p53 knock-out cell lines 
(Fig. 7A)  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 | 8-Azaguanine causes cell death more efficiently in most of the aneuploid AML clones  
 
(A) Cell viability after 48 hours of treatment. (B) Apoptosis assay after 48 and 72 hours of treatment. 
(C) Apoptosis assay after 48 and 72 hours of treatment in p53 knock-out (ko) cells. The graphs show 
mean ± SD (*, 0.05>p≥0.01; **, 0.01>p≥0.001; ***, p<0.001).  
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4.5 Evaluation of 8-azaguanine mechanisms of action 
4.5.1 8-Azaguanine induces ER stress  
Bulk RNA sequencing (RNA-seq) was performed on the p53 wild-type EEB-derived clones. Distance 
matrix analysis of the Spearman rank correlation of all untreated p53 wild-type EEB clones showed 
high similarity among the transcriptomes of euploid and hypodiploid cells and among the 
transcriptomes of the non-responder aneuploid clones (Fig. 14A). These similarities were still 
consistent after drug treatment (Fig. 14B). Principal component analysis and unsupervised clustering 
separated samples, both untreated and treated, according to the responsiveness to 8-azaguanine 
(Fig. 15).  
Ingenuity® Pathway Analysis (IPA®) of untreated aneuploid versus the euploid clone revealed that all 
of the aneuploid clones, with the exception of the hypodiploid one, exhibit upregulation of the NF-κB 
signaling pathway and downregulation of the NRF2-mediated oxidative-stress response pathway 
(Tab. S4).  
Upstream regulator analysis of the non-responder aneuploid clones by IPA® predicted ATF4, 
thapsigargin, hydrogen peroxide, lipopolysaccaride (LPS) and cisplatin as inactivated upstream 
regulators (Tab. S5). 
Among the 50 most differentially expressed genes between each of the 8-azaguanine treated 
samples and the respective untreated control, RNA-seq revealed remarkable similarities among all 
clones and identified a significant deregulation of genes involved in ER stress and cell differentiation. 
The top 30 most significantly deregulated genes in treated versus untreated clones included, among 
the overexpressed, mainly genes related to ER stress (ATF3, HSPA13, INHBE, TRIB3, XBP1, DDIT3, 
ERN1, FAM129, MAP1LC3B, TNFRSF10B, ASNS, HERPUD1, CHAC1), but also genes involved in 
apoptosis (IL6ST, PMAIP1, MXD1) and response to stress (GDF15, SESN2) (Fig. 16A; Tab. S3). 
Moreover, CHOP, encoded by the DDIT3 gene, one of the most upregulated genes in the presence of 
ER stress
118,119
, was activated in all clones after 24 hours of 8-azaguanine treatment (Fig. 16B). 
Treatment, predominantly in the responder clones, also led to the activation of JNK, which is 
involved in IRE1-mediated apoptosis induction
120
 (Fig. 16B). Among the downregulated genes no 
main category could be identified. ER stress and oxidative stress were also shown as active processes 
within all clones treated with 8-azaguanine according to the IPA® analysis of the upstream regulators 
(activated: ATF4, DDIT3, EIF2AK3, thapsigargin, tunicamycin, LPS; inactivated: N-acetyl-L-cysteine 
(NAC)) (Tab. S7).  
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Furthermore, Gene Set Enrichment Analysis (GSEA), a computational technique used in the analysis 
of gene expression data, revealed significantly altered pathways. Kyoto Encyclopedia of Genes and 
Genomes (KEGG) was used as annotation database source of gene sets for the GSEA. Pathways 
involved in DNA replication, purine and pyrimidine metabolism, drug metabolism and ribosomal 
function were significantly downregulated in treated clones compared to the untreated ones (Fig. 
16C). Nucleotide metabolism downregulation was also identified by IPA® pathway analysis (Tab. S6). 
Among the deregulated pathways after treatment, mitogen-activated protein kinase (MAPK) 
signaling was upregulated (Fig. 15C; Tab. S6). p38 MAPK is described to be involved in CHOP 
activation via phosphorylation of its transactivation domain
121
. 
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Figure 14 | Transcriptome similarities between responder and non-responder clones 
 
Distance matrix of the Spearman rank correlation of all (A) untreated and (B) treated EEB-derived 
clones. 
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Figure 15 | Transcriptional 
differences between 
isogenic clones 
(A, B) Principal component 
analysis and (C, D) 
unsupervised clustering of 
untreated and treated (8-
azaguanine 1.25 µM, 24 
hours) samples. 
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Figure 16 | 8-Azaguanine induces ER stress and deregulation of pathways related to MAPK 
signaling, DNA replication, nucleosides metabolism, drug metabolism and ribosomal function 
 
(A) Volcano plot showing the top 30 most significant deregulated genes. (B) 8-Azaguanine triggers 
CHOP and JNK activation as shown by Western blot analysis of cell lysates after 24 hours of 
treatment with 8-azaguanine. (C) Most significantly deregulated KEGG pathways in all treated clones 
in comparison to untreated samples, as shown by GSEA. 
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4.5.2 8-Azaguanine triggers apoptosis  
In order to confirm the observations made with the apoptosis assay, the activation of the apoptosis 
pathway was investigated at the Western blot level. Caspase 3, the executioner caspase, was cleaved 
and thus activated after treatment with 8-azaguanine (Fig. 17B). Active caspase 3 is responsible for 
the cleavage of PARP (Fig. 17B). The executioner caspase is activated by the action of the initiator 
caspases, caspase 8 and caspase 9. These two proteins initiate the apoptotic pathway in response to 
extrinsic and intrinsic stimuli, respectively. In our model system, 8-azaguanine induced apoptosis 
through the activation of the intrinsic pathway. Indeed, caspase 9 was cleaved, whereas caspase 8 
was not activated (Fig. 17A). Caspase 2, which is mostly considered as an initiator caspase, was 
activated as well (Fig. 17B). The activation of the analyzed caspases was more pronounced in the 
three responder aneuploid clones as compared to the euploid and the two non-responder aneuploid 
clones (Fig. 17A-B). 
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Figure 17 | Apoptosis is triggered after 8-azaguanine treatment 
 
(A) Caspase 9 activation and (B) caspase 3, PARP and caspase 2 cleavage, as shown by Western blot 
analysis of cell lysates after 48 hours of treatment with 8-azaguanine. A doxorubicin treated sample 
(Doxo) was used as a positive control. (C) Time course evaluation of caspase 3/7 activity after 
treatment with 1.25 µM 8-azaguanine.  
Caspase 3/7 activity was also measured by Caspase-Glo® assay. The three responder aneuploid 
clones reached a higher peak of caspase 3/7 activation in comparison to the euploid and the two 
non-responder aneuploid clones. Moreover, considering the responder aneuploid clones, the 
caspase activity peaked at 24 hours for the clone with trisomy 7 and 21, whereas for the hypodiploid 
and the near-tetraploid clones it peaked at 48 hours and remained at high levels even at 72 hours 
(Fig. 17C). 
4.5.3 8-Azaguanine causes DNA damage  
To determine whether 8-azaguanine treatment leads to DNA damage the phosphorylation of histone 
H2AX on Ser139 (ɣ-H2AX) was evaluated by immunoblotting. H2AX phosphorylation occurs early 
after DNA damage, and is particularly induced by DNA double strands breaks (DSBs), in order to 
recruit DNA repair proteins
122
. We also determined the occurrence of ɣ-H2AX and tumor suppressor 
p53 binding protein 1 (53BP1)-containing nuclear bodies by immunofluorescence microscopy. 53BP1 
foci have been described to mark unrepaired DNA lesions that persist during mitosis and co-localize 
with ɣ-H2AX
123
. Treatment with 8-azaguanine caused a significant increase of ɣ-H2AX in all of the 
clones, as shown by Western blotting, as well as an increase of ɣ-H2AX/53BP1 foci, as shown by 
immunofluorescence microscopy (Fig. 18A-B). Moreover, the intensity of ɣ-H2AX was higher in the 
three responder aneuploid clones in comparison to the euploid clone (Fig. 18A). The near-tetraploid 
clone showed a basal, treatment-independent level of DSBs, possibly due to an increased amount of 
spontaneous DNA damage in comparison to near-diploid cells, and to either a possible saturation or 
less efficient DNA damage-repair mechanisms.  
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Figure 18 | DNA damage after 8-azaguanine treatment 
 
(A) Phosphorylation of H2AX, as shown by Western blot analysis of cell lysates after 48 hours of 8-
azaguanine treatment. (B) Representative immunofluorescence microscopy image of the euploid 
clone (46, XY) showing increased amounts of 53BP1 and ɣ-H2AX foci at increasing 8-azaguanine 
concentrations (scale bar, 10 µM). 
4.5.4 8-Azaguanine causes cell cycle arrest  
48 hours after 8-azaguanine treatment cell cycle progression was evaluated by FACS analysis. The 
addition of the compound induced cell cycle arrest in G2/M (Fig. 19A). Inhibition of cell cycle 
progression was not dependent on p53 activation. Indeed, p53 knock-out cells were arrested as well 
after treatment with the drug (Fig. 19B). 
 
 
 
 
 
 
Figure 19 | 8-Azaguanine treatment causes cell cycle arrest  
 
Accumulation of cells in G2/M phase after 48 hours of treatment with 8-azaguanine in both (A) p53 
wild-type and (B) p53 knock-out (ko) cells, as shown by FACS analysis.  
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4.5.5 Cell cycle arrest induced by 8-azaguanine treatment is mediated by phospho-ERK1/2 
To further evaluate the mechanisms of 8-azaguanine activity we tested one MAPK key protein to 
investigate whether the MAPK pathway is involved in the cellular response to 8-azaguanine. 
Treatment with 1.25 µM of the compound for 48 hours led to increased levels of extracellular signal-
regulated kinase 1/2 (ERK1/2) phosphorylation (Fig. 20A). This suggests that 8-azaguanine induces at 
least one branch of the MAPK signaling pathway. 
Since phospho-ERK1/2 has already been described by others as a mediator of G2/M cell cycle arrest 
and p21 induction
124
, we hypothesized a possible role of phospho-ERK1/2 in 8-azaguanine induced 
cell cycle arrest as well. To further analyse this hypothesis, we next inhibited mitogen-activated 
protein kinase (MEK) kinase by U0126 to prevent the subsequent ERK1/2 phosphorylation. As 
expected, cells treated with 8-azaguanine alone were arrested in G2/M phase. The addition of U0126 
together with 8-azaguanine prevented this cell cycle arrest. This effect could already be detected 
with 1 µM of the inhibitor, but was enhanced at 2.5 µM. The inhibitor alone, in control cells, at both 
1 and 2.5 µM, did not show any effect on cell cycle progression (Fig. 20B). At the Western blot level it 
was possible to detect a decrease of phospho-ERK1/2 and p21 with the addition of 2.5 µM of U0126 
in comparison to 8-azaguanine treatment alone (Fig. 20C). 
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Figure 20 | Phospho-ERK1/2 mediates 8-azaguanine-induced G2/M cell cycle arrest 
 
(A) Increase of phospho-ERK1/2 and p21 overexpression, as shown by Western blot analysis of cell 
lysates after 48 hours of treatment with 8-azaguanine. (B) Cell cycle arrest in G2/M phase induced by 
8-azaguanine treatment and U0126-dependent cell cycle arrest rescue, as shown by FACS analysis.(C) 
Decrease of ERK1/2 phosporylation and p21 upregulation after combined treatment with 8-
azaguanine and 2.5 µM U0126, as shown by Western blot analysis of cell lysates after 48 hours of 
treatment. 
4.5.6 8-Azaguanine causes cell differentiation 
Cell surface markers (CD13, CD16, CD117, HLA-DR, CD10, CD11b, CD35, CD64, CD14, CD300, CD36, 
CD105, CD71, CD33, CD56, CD19, CD7, CD15, NG2, CD38, CD22) were evaluated by flow cytometry 
before and after 24 hours of 8-azaguanine treatment. Among all the markers tested, only CD117, also 
known as C-KIT, decreased after treatment in the three responder aneuploid clones and in the 
euploid clone. On the other hand, the two non-responder clones already showed low levels of CD117 
before treatment. According to the RNA-seq analysis of untreated cells, C-KIT was one of the most 
significantly downregulated genes in these two clones (padj= 1,85E-43). 
CD117 (% ± SD) Control 8-Aza 
46, XY 73.1 ± 6.1 26.9 ± 8 
45, X, -Y 74.45 ± 1.05 33.45 ± 2.05 
90, XX, -Y, -Y 80.9 ± 2.3 47.85 ± 17.05 
47, XY, +12 18.3 ± 5 5.45 ± 1.75 
47, XY, +22 17.3 ± 1.9 7.5 ± 3.6 
47, X, -Y, +7, +21 66.9 ± 3 23.65 ± 1.65 
 
Table 28 | CD117 expression decreases after 8-azaguanine treatment 
B C 
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5 Discussion 
Pathway deregulation, hampered proliferation, increased energy and metabolic requests, 
proteotoxic stress and genomic instability are typical features of aneuploid cells. Given the 
detrimental consequences of aneuploidy, it is evident why its prevalence in somatic cells is low
7
. 
Although the dismal effects of aneuploidy are well described, karyotype imbalances may confer 
proliferative advantages and promote tumorigenesis. Indeed, under specific circumstances, 
chromosome aberrations can have a tumor suppressor role, but once aneuploid cells overcome 
certain limitations, aneuploidy itself becomes beneficial for cancer development. Aneuploidy is in 
fact a common characteristic of 85% of both solid and hematological tumors and of 60% of AML at 
first diagnosis
15,91
. Moreover, many cancer cells not only harbor aneuploidy, but also chromosomal 
instability with high rates of chromosome missegregation at each cell division, eventually favoring 
cancer evolution by generating intra-tumor genetic diversity.  
Recent studies have started to investigate whether aneuploidy can constitute a potential 
therapeutical target in cancer treatment. These studies were performed using aneuploid MEFs, 
HCT116, RPE-1 and other cell lines
60,61,74
. The effectiveness of the identified aneuploidy-selective 
antiproliferative compounds was mainly attributable to increased levels of stress induced by 
chromosome copy number changes. 
So far, no study evaluating potential aneuploidy-selective antiproliferative compounds in AML has 
been reported. Patients with AML that harbor complex karyotypes have poor prognosis after 
treatment with the conventional chemotherapy, consisting in the combination of the nucleoside 
analog cytarabine and the anthracycline daunorubicin. Since the effectiveness of compounds 
specifically targeting aneuploidy has been demonstrated in other cancer types in vitro, the 
identification of drugs with selective efficacy against aneuploid karyotypes for the treatment of AML 
appears as a reasonable and competitive approach. 
8-Azaguanine is a drug with selective activity against aneuploid AML primary samples and 
cell lines 
Since aneuploid cells derived from different organisms and different cell lines share common 
characteristics that can be exploited as targets for cancer therapy, aneuploidy-selective 
antiproliferative compounds already described in the literature might be effective against aneuploid 
AML cells as well. Therefore 8-azaguanine, 17-AAG, AICAR, ASA, chloroquine, metformin and 
resveratrol were tested on primary AML samples. Centrinone, cisplatin, crenolanib, taxol and 
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vincristine were tested as well. In addition, cytarabine and daunorubicin, which are used in daily 
practice for AML treatment, were also included in the analysis.  
8-Azaguanine was the only compound with selective activity against complex karyotype AML primary 
samples as compared to normal karyotype AML. Moreover, our results suggest that the efficacy of 8-
azaguanine towards primary samples may be influenced by the degree of aneuploidy, independent of 
the preponderance of chromosome gains or losses. 
The comparison between euploid and aneuploid AML cells in vitro is hampered by the lack of suitable 
AML cell line models. Additionally, the comparison of cell lines with different genetic backgrounds 
shows many limitations. Therefore, we established an isogenic AML cell model. For this purpose, a 
euploid clone and spontaneously arising aneuploid cells were isolated from the EEB AML cell line and 
additionally, with the induction of chromosome retention at spindle poles and the inactivation of the 
mitotic checkpoint via CENP-E and MPS1 inhibition, three more aneuploid clones were generated.  
In our EEB AML cell line model, 8-azaguanine was more effective against three out of five p53 wild-
type aneuploid clones versus the euploid clone, partially confirming the results obtained with 
primary AML samples. We hypothesize that the unresponsiveness of two aneuploid cell lines might 
be due, at least in part, to their differentiation status. The EEB cell line belongs to the erythroid 
lineage and expresses CD117/C-KIT. With the increasing differentiation, erythroid precursors 
progressively loose the expression of CD117. C-KIT is a tyrosine-protein kinase that acts as cell-
surface receptor for the cytokine KITLG/SCF. In response to KITLG/SCF binding, C-KIT can activate 
several signaling pathways and plays a crucial role in the regulation of hematopoiesis, cell survival 
and proliferation. We could demonstrate that all responder clones including the euploid one 
expressed high levels of CD117 which were reduced after drug treatment, suggesting an impact of 8-
azaguanine on cell differentiation. On the other hand, CD117 was almost completely absent from the 
non-responder clones, indicating more advanced differentiation. 
The near-tetraploid clone responded best to the drug, suggesting that the extent of aneuploidy might 
influence the response to 8-azaguanine – similar to the situation in primary AML cells – as well. 
Based on this observation we argue that 8-azaguanine has a stronger effect on cells with a high 
burden of chromosomal aberrations. Tetraploid or near tetraploid AML is rare, occurring in only 0.7-
1.2% of patients
125
. Although known to have a dismal prognosis, it is not well characterized. Given 
our results, 8-azaguanine could represent an interesting option for the treatment of patients whose 
AML blasts harbor a high number of chromosomal aberrations. 
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We further generated isogenic EEB cells lacking p53, which harbored heterogeneous karyotypes with 
many different numerical and structural aberrations, and demonstrated that 8-azaguanine can be 
effective against chromosomally unstable p53 knock-out EEB AML cells as well. 
8-Azaguanine selectivity against aneuploid cells might be due to an increased burden on 
the ER  
As demonstrated by gene expression analysis and confirmed by Western blotting, 8-azaguanine 
triggers the activation of ER stress pathways. Proteotoxic stress is a well known consequence of 
aneuploidy itself
50,55,57,59,60,61
. Indeed, enhanced protein production in karyotypically abnormal cells 
induces a saturation of the protein folding pathways, which in turn leads to increased amounts of 
misfolded proteins. Once cells sense the insufficiency of the ER protein folding capacity, the unfolded 
protein response (UPR) is triggered and the ER stress sensors ATF6, IRE1 and PERK cause a reduction 
of the protein load to the ER. Furthermore, misfolded proteins that are retained in the ER are 
transported to the cytosol and degraded in a process called ER-associated degradation (ERAD). If the 
stress cannot be solved and homeostasis is not reestablished, cells enter apoptosis. Since proteotoxic 
stress has already been described as a typical consequence of aneuploidy, we argue that in such a 
situation the addition of an ER stress inducing agent as 8-azaguanine pushes cells into apoptosis, 
thereby explaining the aneuploidy-selective antiproliferative effect of the drug. This is indeed 
sustained by our RNA-seq data, which revealed that the untreated aneuploid clones already 
exhibited an upregulation of the NF-κB signaling pathway. NF-κB activation, together with the release 
of Ca
2+
 from the ER and the production of reactive oxygen species, is involved in the ER overload 
response (EOR) which is triggered by the accumulation of membrane proteins in the ER
126
. 
Furthermore, the unresponsiveness to 8-azaguanine of the two non-responder clones could be due 
to their reduced susceptibility to ER stress and higher tolerance to oxidative stress, as suggested by 
the upstream regulator analysis in IPA®.  
Moreover, in our model, 8-azaguanine triggered the activation of the intrinsic apoptosis pathway as 
well as stronger and prolonged activation of the executioner caspase 3 in the responder aneuploid 
clones in comparison to the euploid and the non-responder clones. We therefore suggest that 
apoptosis is caused by massive ER stress and triggered by a downstream effector of the ER stress 
pathway, CHOP, whose expression promotes cell death in the presence of prolonged stress
118,119
,
 
and 
by the activation of IRE1-mediated JNK signaling, which is involved in the inhibition and activation of 
Bcl-2 and Bim, respectively
120,127,128
.  
In all the clones analyzed 8-azaguanine caused cell cycle arrest in G2/M phase through p53-
independent mechanisms, as G2/M arrest was found in p53-deficient clones after drug treatment as 
well. This cell cycle arrest is likely a consequence of extensive DNA damage, which seemed also to be 
Discussion 
69 
 
more enhanced in the aneuploid responder cells in comparison to the euploid clone, even if we 
cannot exclude a possible causative role of ER stress as well. 
p53 deficiency leads to extensive karyotypic heterogeneity and to the propagation of 
structural aberrations 
Aneuploidy, due to its detrimental consequences, which have been already shown at both cellular 
and organismal levels, can lead to p53 activation and inhibition of proliferation. Nevertheless, the 
aspects which determine p53 activation after chromosome missegregation have still to be 
determined. It has been proposed that aneuploidy per se can activate p53 via p38, even without any 
evidence of DNA damage, as described by Thompson and Compton. In this case, p53 activation has 
been suggested to be caused by transcript imbalances of genes located on supernumerary 
chromosomes
68
. On the other hand, others reported that p53 is not directly activated by aneuploidy, 
but via related conditions. Janssen and colleagues observed that chromosome missegregation causes 
DNA damage and, only subsequently, ATM and p53 activation
65
. Li and colleagues reported that after 
chromosome segregation errors elevated levels of ROS were produced, inducing oxidative DNA 
damage, and subsequent ATM and p53 activation
69
. More recent studies showed that p53-mediated 
cell cycle arrest occurs in more severely aneuploid cells with structural abnormalities, as a 
consequence of DNA replication stress
113,114
. These inconsistencies might be due to different 
experimental settings, prolonged mitotic timing that causes a subsequent p53-dependent G1 arrest, 
and undetected DNA damage 
70
.  A clear definition of the mechanisms which link aneuploidy to p53 
activation will help to better define how abnormal karyotypes arise and to understand the acquired 
tolerance of tumor cells to aberrant karyotypes. Another still controversial issue is whether p53 
deficiency itself leads to aneuploidy. Bunz and colleagues have initially investigated this hypothesis in 
HCT116 cells with inactivated p53 and showed that p53 deficiency does not lead to aneuploidy 
development in this system
115
. On the contrary, we demonstrated that AML EEB p53-deficient cells 
can spontaneously acquire and propagate chromosome abnormalities, including numerical 
aneuploidies, structural aneuploidies and structural rearrangements, without the addition of 
missegregation stimuli. We showed that p53 deficiency is sufficient to allow the propagation of 
chromosomal instability at higher rates compared to those obtained after the induction of 
chromosome missegregation in p53 wild-type cells, arguing for the important role of p53 in the 
maintenance of genomic stability. Loss of p53 leads to non-clonal abnormalities and thus allows for 
extensive karyotypic heterogeneity. Taken together our results are consistent with epidemiological 
data. Indeed TP53 alterations are the most frequently described aberrations in patients with complex 
karyotype AML (TP53 mutations and TP53 losses are found in 60%-80% and 40% of AML patients 
with complex karyotype, respectively
129,130
). Furthermore, in complex karyotype AML, cases 
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harboring TP53 alterations are characterized by an increased total number of chromosomal 
aberrations in comparison to complex karyotype AML cells with wild-type TP53
129
. 
In our AML model we demonstrated that numerical aneuploidy can be propagated in p53-proficient 
EEB cells, indicating that aneuploidy does not always lead to p53-mediated cell cycle arrest and cell 
death. On the other hand the presence of p53 limits the propagation of structural aneuploidies and 
structural rearrangements almost completely. These results are in agreement with reports by Soto 
and Santaguida on untransformed RPE-1 cells
113,114
. In our model chromosome missegregation was 
likely triggered to the same extent in both p53-proficient and p53-deficient cells. Since segmental 
aneuploidies and structural rearrangements as well as DNA damage were only detected in the 
absence of p53, our data suggest that chromosome missegregation events resulting in structural 
chromosome abnormalities cause DNA damage with consequential p53-mediated permanent cell 
cycle arrest and/or cell death.  
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6 Outlook 
The present work has led to the identification of 8-azaguanine as a potential AML aneuploidy-
selective anti-cancer drug, as demonstrated in primary AML samples and an isogenic AML cell line 
model. The 8-azaguanine effect seems to be more pronounced in cells harboring a more extensive 
level of aneuploidy, suggesting a potential clinical application in patients with complex karyotype or 
tetraploid AML. Studies evaluating the efficacy of this compound in animal models of complex 
karyotype or tetraploid versus euploid AML are thus required to confirm our in vitro findings. 
8-Azaguanine causes activation of the ER stress response and subsequent cell death possibly by 
exaggerating the basal ER stress level of aneuploid cells, as shown in our cell line model and 
suggested by RNA-seq results. However, additional analyses have to be performed to prove at the 
molecular level the presence of basal ER stress in aneuploid cells. It would be interesting to 
demonstrate a similar pattern also in primary AML samples.   
Additionally, we demonstrated that 8-azaguanine, as a purine analogue, causes DNA damage as a 
consequence of replication impairment, but the characteristics of the compound leading to the 
generation of ER stress remains unclear. 8-Azaguanine mechanisms of action need therefore to be 
investigated in more depth. 
Index 
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7 Index 
7.1 Lists of abbreviations 
Abbreviations  Name 
17-AAG 17-Allylamino-geldanamycin 
AICAR 5-Aminoimidazole-4-carboxamide ribonucleotide 
abn Abnormal 
AML Acute Myeloid Leukemia 
AMPK AMP-Activated Protein Kinase  
APC/C Anaphase Promoting Complex  
APS Aneuploidy-Associated Protein Signature  
APS Ammonium Persulfate 
ASA  Acetylsalicylic Acid 
ATF6 Activating Transcription Factor 6 
AUC  Area Under The Curve 
8-Aza 8-Azaguanine 
BM Bone Marrow  
BMNCs Bone Marrow Mononuclear Cells  
53BP1 Tumor Suppressor p53 Binding Protein 1  
BSA Bovine Serum Albumin 
CDC20 Cell-Division Cycle Protein 20 
CDK1 Cyclin-Dependent Kinase 1 
CENP-E Centromere-Associated Protein-E  
CHOP C/EPB homologous protein 
CI Confidence Interval 
CIN Chromosomal Instability 
CLL Chronic Lymphocytic Leukemia 
ddH2O Double Distilled Water 
DPBQ 2,3-Diphenylbenzo[g]quinoxaline-5,10-dione 
D-PBS Dulbecco’s Phosphate Buffered Saline 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic Acid 
ELN European Leukemianet 
ER Endoplasmic Reticulum 
FAB French-American-British  
FBS Fetal Bovine Serum 
FISH Fluorescence In Situ Hybridization 
GSEA Gene Set Enrichment Analysis 
HSF1 Heat Shock Factor 1  
HSP90 Heat Shock Protein 90 
HSP72 Heat Shock Protein 72 
IC50 Inhibitory Concentration 50% 
IF Immunofluorescence 
inv Inversion 
IPA Ingenuity Pathway Analysis 
IRE1 Inositol-Requiring Enzyme 1 
JNK cJun NH2-Terminal Kinase 
KEGG Kyoto Encyclopedia of Genes and Genomes 
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ko Knock-out 
LB Lysogeny Broth 
LC3 Autophagy Marker Light Chain 3 
LPS Lipopolysaccharide 
MAD2 Mitotic Arrest Deficient 2 
MCM Mononuclear Cell Medium  
MEFs Mouse Embryonic Fibroblasts 
M-FISH Multiplex Fluorescence In Situ Hybridization 
MOPS 3-(N-morpholino)propanesulfonic acid 
MPS1 Multipolar Spindle-1  
MVA Mosaic Variegated Aneuploidy  
NAC N-acetyl-L-cysteine 
p53 Tumor protein p53 
p P Value 
padj P Value Adjusted 
PERK Protein Kinase RNA-Like Endoplasmic Reticulum Kinase 
PB Peripheral Blood  
PBMCs Peripheral blood mononuclear cells  
PBS Phosphate Buffered Saline 
PLK4 Polo-Like Kinase 4  
PNK T4 Polynucleotide Kinase 
RIN RNA Integrity Number 
RNA Ribonucleic acid 
RNA-seq RNA Sequencing 
ROS Reactive Oxygen Species 
SAC Spindle Assembly Checkpoint 
SAP Shrimp Alkaline Phosphatase 
SD Standard Deviation 
sgRNA Single guide RNA 
SOB Super Optimal Broth 
SOC Super Optimal Broth With Catabolite Repression 
SQSTM1 P62/Sequestosome-1  
t Translocation 
TAE Tris-Acetate-EDTA 
TBS-T Tris Buffered Saline with Tween 20 
TEMED Tetramethylethylendiamin 
UPR Unfolded Protein Response 
UV Ultraviolet 
WHO World Health Organization 
wt Wild-type 
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Abbreviations of units Unit 
bp Base Pairs 
°C Degree Celsius 
Da Dalton 
k kilo 
m milli 
µ micro 
M molar 
n nano 
rcf Relative centrifugal force 
rpm Rounds per minute 
V Voltage 
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